Trial Outcomes & Findings for Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin (NCT NCT04563845)

Results Overview

Blood samples were to be collected at indicated time points to analyze the plasma concentration of major metabolites of GSK3640254.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

50 participants

Primary outcome timeframe

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Results posted on

2023-12-06

Participant Flow

This study was conducted at a single center in the United States.

A total of 50 participants (8 in Part 1 and 42 in Part 2) were enrolled in the study (Safety Population: It comprised of all participants who received at least 1 dose of study intervention).

Participant milestones

Participant milestones
Measure	Part 1: Placebo Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.	Part 1: GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg Participants received a single therapeutic dose of GSK3640254 100 mg once daily on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg once daily on Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg/GSK3640254 500 mg Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg/GSK3640254 100 mg Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7(Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg/ Placebo Participants received a single therapeutic dose of GSK3640254 100 mg Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo/GSK3640254 500 mg Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 100 mg/Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg Participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg/GSK3640254 100 mg Participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg/Placebo Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.
Part 1: (Up to Day 9) STARTED	2	6	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: (Up to Day 9) COMPLETED	2	6	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: (Up to Day 9) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2:Treatment Period 1(Up to 7 Days) STARTED	0	0	3	4	4	4	4	3	3	3	4	4	3	3
Part 2:Treatment Period 1(Up to 7 Days) COMPLETED	0	0	3	4	4	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 1(Up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Part 2:Washout Period 1(Up to 7 Days) STARTED	0	0	3	4	4	4	4	2	3	3	4	4	3	3
Part 2:Washout Period 1(Up to 7 Days) COMPLETED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Washout Period 1(Up to 7 Days) NOT COMPLETED	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Part 2:Treatment Period 2(Up to 7 Days) STARTED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 2(Up to 7 Days) COMPLETED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 2(Up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2:Washout Period 2(Up to 7 Days) STARTED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Washout Period 2(Up to 7 Days) COMPLETED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Washout Period 2(Up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2:Treatment Period 3(Up to 7 Days) STARTED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 3(Up to 7 Days) COMPLETED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 3(Up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2:Washout Period 3(Up to 7 Days) STARTED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Washout Period 3(Up to 7 Days) COMPLETED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Washout Period 3(Up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2:Treatment Period 4(Up to 7 Days) STARTED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 4(Up to 7 Days) COMPLETED	0	0	3	4	3	4	4	2	3	3	4	4	3	3
Part 2:Treatment Period 4(Up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Placebo Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.	Part 1: GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg Participants received a single therapeutic dose of GSK3640254 100 mg once daily on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg once daily on Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg/GSK3640254 500 mg Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg/GSK3640254 100 mg Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7(Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg/ Placebo Participants received a single therapeutic dose of GSK3640254 100 mg Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo/GSK3640254 500 mg Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 100 mg/Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg Participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg/GSK3640254 100 mg Participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg/Placebo Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.
Part 2:Treatment Period 1(Up to 7 Days) Adverse Event	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Part 2:Washout Period 1(Up to 7 Days) Withdrawal by Subject	0	0	0	0	1	0	0	0	0	0	0	0	0	0

Baseline Characteristics

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Placebo n=2 Participants Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg n=3 Participants Participants received a single therapeutic dose of GSK3640254 100 mg once daily on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg once daily on Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo n=4 Participants Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg/GSK3640254 500 mg n=4 Participants Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg/GSK3640254 100 mg n=4 Participants Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg n=4 Participants Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7(Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg n=3 Participants Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg/ Placebo n=3 Participants Participants received a single therapeutic dose of GSK3640254 100 mg Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo/GSK3640254 500 mg n=3 Participants Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: Placebo/GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg n=4 Participants Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 100 mg/Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg n=4 Participants Participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.	Part 2: GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg/GSK3640254 100 mg n=3 Participants Participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.	Part 2: Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg/Placebo n=3 Participants Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.	Total n=50 Participants Total of all reporting groups
Age, Customized 18-50 years	2 Participants n=5 Participants	6 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants	4 Participants n=21 Participants	4 Participants n=10 Participants	4 Participants n=115 Participants	3 Participants n=6 Participants	3 Participants n=6 Participants	3 Participants n=64 Participants	4 Participants n=17 Participants	4 Participants n=21 Participants	3 Participants n=22 Participants	3 Participants n=8 Participants	50 Participants n=16 Participants
Age, Customized >50 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	0 Participants n=16 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	4 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	1 Participants n=6 Participants	1 Participants n=64 Participants	3 Participants n=17 Participants	1 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	15 Participants n=16 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	4 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=10 Participants	4 Participants n=115 Participants	3 Participants n=6 Participants	2 Participants n=6 Participants	2 Participants n=64 Participants	1 Participants n=17 Participants	3 Participants n=21 Participants	3 Participants n=22 Participants	3 Participants n=8 Participants	35 Participants n=16 Participants
Race/Ethnicity, Customized Asian-Central/South Asian Heritage	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	1 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	1 Participants n=16 Participants
Race/Ethnicity, Customized Black or African American	1 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	1 Participants n=115 Participants	2 Participants n=6 Participants	3 Participants n=6 Participants	0 Participants n=64 Participants	1 Participants n=17 Participants	1 Participants n=21 Participants	2 Participants n=22 Participants	2 Participants n=8 Participants	20 Participants n=16 Participants
Race/Ethnicity, Customized Native Hawaiian or other pacific islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	1 Participants n=16 Participants
Race/Ethnicity, Customized White	1 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	3 Participants n=115 Participants	1 Participants n=6 Participants	0 Participants n=6 Participants	3 Participants n=64 Participants	2 Participants n=17 Participants	3 Participants n=21 Participants	1 Participants n=22 Participants	1 Participants n=8 Participants	28 Participants n=16 Participants

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Population: Pharmacokinetic Parameter Population comprised of all participants who undergone plasma PK sampling and had evaluable PK parameters estimated. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254	102400 Hours*nanograms per milliliter Geometric Coefficient of Variation 25.3	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Population: Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254	68790 Hours*nanograms per milliliter Geometric Coefficient of Variation 25.1	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Population: Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Maximum Observed Concentration (Cmax) of GSK3640254	4439 Nanograms per milliliter Geometric Coefficient of Variation 22.7	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Population: Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of GSK3640254	2081 Nanograms per milliliter Geometric Coefficient of Variation 32.4	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Population: Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Time of Maximum Observed Concentration (Tmax) of GSK3640254	4.500 Hours Interval 2.0 to 4.5	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

Population: Pharmacokinetic concentration Population comprised of all participants who undergone plasma PK sampling and had evaluable PK assay results. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze the plasma concentration of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Plasma Concentration of GSK3640254 12 Hour, Day 7	2773 Nanograms per milliliter Standard Deviation 535.66	—	—	—
Part 1: Plasma Concentration of GSK3640254 Pre-dose, Day 7	2168 Nanograms per milliliter Standard Deviation 668.17	—	—	—
Part 1: Plasma Concentration of GSK3640254 30 minutes, Day 7	2000 Nanograms per milliliter Standard Deviation 638.53	—	—	—
Part 1: Plasma Concentration of GSK3640254 1 Hour, Day 7	2579 Nanograms per milliliter Standard Deviation 972.02	—	—	—
Part 1: Plasma Concentration of GSK3640254 2 Hour, Day 7	3513 Nanograms per milliliter Standard Deviation 1297.2	—	—	—
Part 1: Plasma Concentration of GSK3640254 3 Hour, Day 7	4228 Nanograms per milliliter Standard Deviation 997.39	—	—	—
Part 1: Plasma Concentration of GSK3640254 3 Hours 30 minutes, Day 7	4155 Nanograms per milliliter Standard Deviation 1042.5	—	—	—
Part 1: Plasma Concentration of GSK3640254 4 Hour, Day 7	4213 Nanograms per milliliter Standard Deviation 921.36	—	—	—
Part 1: Plasma Concentration of GSK3640254 4 Hours 30 minutes, Day 7	4452 Nanograms per milliliter Standard Deviation 916.01	—	—	—
Part 1: Plasma Concentration of GSK3640254 5 Hour, Day 7	3840 Nanograms per milliliter Standard Deviation 1299.8	—	—	—
Part 1: Plasma Concentration of GSK3640254 6 Hour, Day 7	4010 Nanograms per milliliter Standard Deviation 934.73	—	—	—
Part 1: Plasma Concentration of GSK3640254 24 Hour, Day 7	2115 Nanograms per milliliter Standard Deviation 640.77	—	—	—
Part 1: Plasma Concentration of GSK3640254 48 Hour, Day 7	1070 Nanograms per milliliter Standard Deviation 412.36	—	—	—

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Baseline (Day -2)	4.740 10^12 cells per liter Standard Deviation 0.0849	4.647 10^12 cells per liter Standard Deviation 0.3336	—	—
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Day 7	5.060 10^12 cells per liter Standard Deviation 0.3677	4.915 10^12 cells per liter Standard Deviation 0.3246	—	—
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Day 3	5.010 10^12 cells per liter Standard Deviation 0.3253	4.820 10^12 cells per liter Standard Deviation 0.2626	—	—
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Day 9	5.065 10^12 cells per liter Standard Deviation 0.2475	4.852 10^12 cells per liter Standard Deviation 0.2556	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin Day 3	6.0 Grams per liter Standard Deviation 5.66	5.5 Grams per liter Standard Deviation 6.95	—	—
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin Day 7	8.0 Grams per liter Standard Deviation 7.07	8.7 Grams per liter Standard Deviation 8.29	—	—
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin Day 9	8.5 Grams per liter Standard Deviation 2.12	5.8 Grams per liter Standard Deviation 10.30	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated timepoints to analyze hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Hematology Parameter: Hematocrit Day 9	0.0310 Proportion of red blood cells in blood Standard Deviation 0.01414	0.0142 Proportion of red blood cells in blood Standard Deviation 0.03330	—	—
Part 1: Change From Baseline in Hematology Parameter: Hematocrit Day 3	0.0210 Proportion of red blood cells in blood Standard Deviation 0.02404	0.0128 Proportion of red blood cells in blood Standard Deviation 0.01779	—	—
Part 1: Change From Baseline in Hematology Parameter: Hematocrit Day 7	0.0250 Proportion of red blood cells in blood Standard Deviation 0.02404	0.0220 Proportion of red blood cells in blood Standard Deviation 0.02194	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	-0.40 Femtoliter Standard Deviation 0.283	-0.37 Femtoliter Standard Deviation 0.709	—	—
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 9	0.50 Femtoliter Standard Deviation 0.424	-0.75 Femtoliter Standard Deviation 0.802	—	—
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 3	-0.40 Femtoliter Standard Deviation 0.849	-0.47 Femtoliter Standard Deviation 0.403	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at idicated time points to analyze erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 3	-0.50 Picograms Standard Deviation 0.141	0.08 Picograms Standard Deviation 0.343	—	—
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 7	-0.35 Picograms Standard Deviation 0.071	0.15 Picograms Standard Deviation 0.501	—	—
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 9	-0.35 Picograms Standard Deviation 0.354	-0.02 Picograms Standard Deviation 0.412	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze the hematology parameter: Erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Day 3	0.270 10^12 cells per liter Standard Deviation 0.2404	0.173 10^12 cells per liter Standard Deviation 0.2062	—	—
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Day 7	0.320 10^12 cells per liter Standard Deviation 0.2828	0.268 10^12 cells per liter Standard Deviation 0.2513	—	—
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Day 9	0.325 10^12 cells per liter Standard Deviation 0.1626	0.205 10^12 cells per liter Standard Deviation 0.3761	—	—

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Albumin, Day 3	46.0 Grams per liter Standard Deviation 1.41	41.8 Grams per liter Standard Deviation 3.31	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Albumin, Baseline (Day -2)	46.5 Grams per liter Standard Deviation 2.12	43.0 Grams per liter Standard Deviation 3.03	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Albumin, Day 7	47.5 Grams per liter Standard Deviation 0.71	44.3 Grams per liter Standard Deviation 3.61	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Albumin, Day 9	45.5 Grams per liter Standard Deviation 0.71	43.2 Grams per liter Standard Deviation 2.64	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Globulin, Baseline (Day -2)	26.5 Grams per liter Standard Deviation 2.12	25.5 Grams per liter Standard Deviation 5.13	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Globulin, Day 3	26.0 Grams per liter Standard Deviation 0.00	27.7 Grams per liter Standard Deviation 2.34	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Globulin, Day 7	25.0 Grams per liter Standard Deviation 1.41	27.8 Grams per liter Standard Deviation 3.66	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Globulin, Day 9	25.5 Grams per liter Standard Deviation 0.71	27.5 Grams per liter Standard Deviation 4.28	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Total protein, Baseline (Day -2)	73.0 Grams per liter Standard Deviation 4.24	68.5 Grams per liter Standard Deviation 5.47	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Total protein, Day 3	72.0 Grams per liter Standard Deviation 1.41	69.5 Grams per liter Standard Deviation 3.27	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Total protein, Day 7	72.5 Grams per liter Standard Deviation 2.12	72.2 Grams per liter Standard Deviation 4.07	—	—
Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein Total Bilirubin, Day 9	71.0 Grams per liter Standard Deviation 1.41	70.7 Grams per liter Standard Deviation 4.76	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated timepoints to analyze amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Baseline (Day -2)	64.5 Units per liter Standard Deviation 26.16	63.8 Units per liter Standard Deviation 22.54	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Day 3	64.0 Units per liter Standard Deviation 33.94	61.8 Units per liter Standard Deviation 25.31	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Day 7	67.0 Units per liter Standard Deviation 45.25	62.8 Units per liter Standard Deviation 22.45	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Day 9	64.5 Units per liter Standard Deviation 41.72	59.5 Units per liter Standard Deviation 22.05	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Baseline (Day -2)	33.5 Units per liter Standard Deviation 20.51	35.5 Units per liter Standard Deviation 11.84	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Day 3	18.5 Units per liter Standard Deviation 2.12	30.2 Units per liter Standard Deviation 12.24	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Day 7	19.5 Units per liter Standard Deviation 3.54	32.3 Units per liter Standard Deviation 16.24	—	—
Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Day 9	18.5 Units per liter Standard Deviation 3.54	29.3 Units per liter Standard Deviation 11.29	—	—

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze glucose, cholesterol, magnesium, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium, and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day -2), Day 3, Day 7, and Day 9

Population: Safety Population

Blood samples were collected at indicated time points to analyze ALT, ALP, AST, GGT, creatine kinase, and lactate dehydrogenase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

PRIMARY outcome

Timeframe: Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9

Population: Safety Population

Pulse rate was measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 3	70.5 Beats per minute (bpm) Standard Deviation 2.12	65.0 Beats per minute (bpm) Standard Deviation 10.24	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 7	70.0 Beats per minute (bpm) Standard Deviation 7.07	70.5 Beats per minute (bpm) Standard Deviation 7.50	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 8	70.0 Beats per minute (bpm) Standard Deviation 8.49	81.3 Beats per minute (bpm) Standard Deviation 9.63	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 9	73.0 Beats per minute (bpm) Standard Deviation 2.83	67.8 Beats per minute (bpm) Standard Deviation 9.02	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Baseline (Pre-dose, Day 1 )	70.5 Beats per minute (bpm) Standard Deviation 7.78	67.8 Beats per minute (bpm) Standard Deviation 13.44	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 2	63.0 Beats per minute (bpm) Standard Deviation 7.07	68.7 Beats per minute (bpm) Standard Deviation 10.60	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 4	71.0 Beats per minute (bpm) Standard Deviation 5.66	68.8 Beats per minute (bpm) Standard Deviation 12.29	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 5	67.0 Beats per minute (bpm) Standard Deviation 14.14	72.5 Beats per minute (bpm) Standard Deviation 12.32	—	—
Part 1: Absolute Values for Vital Parameter: Pulse Rate Day 6	66.5 Beats per minute (bpm) Standard Deviation 3.54	67.2 Beats per minute (bpm) Standard Deviation 8.57	—	—

PRIMARY outcome

Timeframe: Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9

Population: Safety Population

Temperature was measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Vital Parameter: Temperature Day 2	36.10 Degrees Celsius Standard Deviation 0.424	36.53 Degrees Celsius Standard Deviation 0.225	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 3	36.10 Degrees Celsius Standard Deviation 0.283	36.58 Degrees Celsius Standard Deviation 0.264	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 4	36.15 Degrees Celsius Standard Deviation 0.354	36.52 Degrees Celsius Standard Deviation 0.479	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 9	36.35 Degrees Celsius Standard Deviation 0.212	36.47 Degrees Celsius Standard Deviation 0.234	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Baseline (Pre-dose, Day 1)	35.90 Degrees Celsius Standard Deviation 0.424	36.50 Degrees Celsius Standard Deviation 0.341	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 5	36.35 Degrees Celsius Standard Deviation 0.354	36.58 Degrees Celsius Standard Deviation 0.360	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 6	36.45 Degrees Celsius Standard Deviation 0.354	36.47 Degrees Celsius Standard Deviation 0.250	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 7	35.95 Degrees Celsius Standard Deviation 0.495	36.47 Degrees Celsius Standard Deviation 0.383	—	—
Part 1: Absolute Values for Vital Parameter: Temperature Day 8	36.35 Degrees Celsius Standard Deviation 0.071	36.63 Degrees Celsius Standard Deviation 0.280	—	—

PRIMARY outcome

Timeframe: Baseline (Pre-dose, Day 1) and up to Day 7

Population: PK/QTc Population comprised of all participants who are in both QT/QTc and PK concentration Populations with at least 1 pair of post-dose PK and change from Baseline in QTc data from the same time point as well as participants in the QT/QTc Population who received placebo. Only those participants with data available at specified time points were analyzed. This outcome measure(OM) intended to provide Placebo-corrected data. Summary of change from Baseline data is provided in OM43.

Twelve-lead ECGs were recorded in participant using automated ECG machine \& performed with participant in supine position after a rest of at least 10 minutes.Baseline was defined as the latest pre-dose assessment with a non-missing value for each visit. Change from Baseline was calculated by subtracting Baseline value from post dose value. Placebo-corrected change from Baseline in QT interval corrected for heart rate using Fridericia's formula (QTcF) was calculated as difference in model-predicted mean change from Baseline in QTcF between treatment groups using C-QTc analysis. A linear mixed-effects model with change from Baseline in QTcF as the dependent variable, time-matched GSK3640254 plasma concentration as a fixed effect, centered Baseline as additional covariate,treatment \&time as categorical factors, \& a random intercept \& slope per participant. In all calculations, concentrations in participants who received placebo were set to 0.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=39 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) Following Administration of GSK3640254 100 mg and GSK3640254 500 mg Using Concentration-QTc (C-QTc) Analysis	2.72 Milliseconds (ms) Interval 2.04 to 3.39	11.49 Milliseconds (ms) Interval 9.24 to 13.73	—	—

PRIMARY outcome

Timeframe: Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each treatment period

Population: Pharmacokinetic Concentration Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze the plasma concentration of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Plasma Concentration of GSK3640254 24 Hour, Day 7	469.9 Nanograms per milliliter Standard Deviation 183.24	2257 Nanograms per milliliter Standard Deviation 1127.6	—	—
Part 2: Plasma Concentration of GSK3640254 Pre-dose, Day 7	496.0 Nanograms per milliliter Standard Deviation 209.03	2357 Nanograms per milliliter Standard Deviation 1137.1	—	—
Part 2: Plasma Concentration of GSK3640254 30 minutes, Day 7	462.3 Nanograms per milliliter Standard Deviation 188.61	2252 Nanograms per milliliter Standard Deviation 1266.0	—	—
Part 2: Plasma Concentration of GSK3640254 1 Hour, Day 7	486.6 Nanograms per milliliter Standard Deviation 198.56	2339 Nanograms per milliliter Standard Deviation 1289.3	—	—
Part 2: Plasma Concentration of GSK3640254 2 Hour, Day 7	587.8 Nanograms per milliliter Standard Deviation 298.21	2779 Nanograms per milliliter Standard Deviation 1670.6	—	—
Part 2: Plasma Concentration of GSK3640254 3 Hour, Day 7	682.4 Nanograms per milliliter Standard Deviation 329.52	3372 Nanograms per milliliter Standard Deviation 1757.9	—	—
Part 2: Plasma Concentration of GSK3640254 3 Hours 30 minutes, Day 7	738.6 Nanograms per milliliter Standard Deviation 368.38	3698 Nanograms per milliliter Standard Deviation 1812.2	—	—
Part 2: Plasma Concentration of GSK3640254 4 Hour, Day 7	765.5 Nanograms per milliliter Standard Deviation 349.05	4011 Nanograms per milliliter Standard Deviation 1880.5	—	—
Part 2: Plasma Concentration of GSK3640254 4 Hours 30 minutes, Day 7	782.4 Nanograms per milliliter Standard Deviation 318.09	4157 Nanograms per milliliter Standard Deviation 1927.0	—	—
Part 2: Plasma Concentration of GSK3640254 5 Hour, Day 7	811.3 Nanograms per milliliter Standard Deviation 326.24	4172 Nanograms per milliliter Standard Deviation 1804.9	—	—
Part 2: Plasma Concentration of GSK3640254 6 Hour, Day 7	769.8 Nanograms per milliliter Standard Deviation 265.82	4102 Nanograms per milliliter Standard Deviation 1719.5	—	—
Part 2: Plasma Concentration of GSK3640254 8 Hour, Day 7	740.9 Nanograms per milliliter Standard Deviation 280.65	3762 Nanograms per milliliter Standard Deviation 1727.0	—	—
Part 2: Plasma Concentration of GSK3640254 10 Hour, Day 7	698.7 Nanograms per milliliter Standard Deviation 280.28	3564 Nanograms per milliliter Standard Deviation 1603.7	—	—
Part 2: Plasma Concentration of GSK3640254 12 Hour, Day 7	625.4 Nanograms per milliliter Standard Deviation 231.50	3098 Nanograms per milliliter Standard Deviation 1347.5	—	—

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze Erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Baseline (Day -2)	4.859 10^12 cells per liter Standard Deviation 0.4614	4.815 10^12 cells per liter Standard Deviation 0.4808	4.829 10^12 cells per liter Standard Deviation 0.4842	4.864 10^12 cells per liter Standard Deviation 0.5017
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Day 14	4.782 10^12 cells per liter Standard Deviation 0.4689	4.780 10^12 cells per liter Standard Deviation 0.4388	4.866 10^12 cells per liter Standard Deviation 0.5418	4.910 10^12 cells per liter Standard Deviation 0.5078
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Day 8	4.775 10^12 cells per liter Standard Deviation 0.4512	4.833 10^12 cells per liter Standard Deviation 0.4585	4.794 10^12 cells per liter Standard Deviation 0.5278	4.927 10^12 cells per liter Standard Deviation 0.5074
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Day 9	4.890 10^12 cells per liter Standard Deviation 0.6010	4.737 10^12 cells per liter Standard Deviation 0.4416	5.023 10^12 cells per liter Standard Deviation 0.3646	4.632 10^12 cells per liter Standard Deviation 0.3654

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin Day 8	-2.7 Grams per liter Standard Deviation 5.58	0.1 Grams per liter Standard Deviation 6.08	-0.9 Grams per liter Standard Deviation 6.20	0.3 Grams per liter Standard Deviation 4.45
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin Day 9	-0.6 Grams per liter Standard Deviation 5.17	-1.3 Grams per liter Standard Deviation 5.87	1.0 Grams per liter Standard Deviation 6.54	0.0 Grams per liter Standard Deviation 4.78
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin Day 14	-1.9 Grams per liter Standard Deviation 6.15	-0.2 Grams per liter Standard Deviation 5.43	0.8 Grams per liter Standard Deviation 7.32	-0.9 Grams per liter Standard Deviation 4.53

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze hematocrit . Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Hematology Parameter: Hematocrit Day 14	-0.0052 Proportion of red blood cells in blood Standard Deviation 0.01837	-0.0012 Proportion of red blood cells in blood Standard Deviation 0.01728	0.0035 Proportion of red blood cells in blood Standard Deviation 0.02158	-0.0026 Proportion of red blood cells in blood Standard Deviation 0.01427
Part 2: Change From Baseline in Hematology Parameter: Hematocrit Day 8	-0.0068 Proportion of red blood cells in blood Standard Deviation 0.01715	0.0002 Proportion of red blood cells in blood Standard Deviation 0.01915	-0.0018 Proportion of red blood cells in blood Standard Deviation 0.01861	-0.0040 Proportion of red blood cells in blood Standard Deviation 0.01256
Part 2: Change From Baseline in Hematology Parameter: Hematocrit Day 9	-0.0009 Proportion of red blood cells in blood Standard Deviation 0.01290	-0.0076 Proportion of red blood cells in blood Standard Deviation 0.01928	0.0036 Proportion of red blood cells in blood Standard Deviation 0.02174	-0.0007 Proportion of red blood cells in blood Standard Deviation 0.01843

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 8	-0.57 Femtoliter Standard Deviation 2.043	-0.26 Femtoliter Standard Deviation 0.748	-0.45 Femtoliter Standard Deviation 0.720	-0.55 Femtoliter Standard Deviation 2.011
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 9	0.15 Femtoliter Standard Deviation 0.438	0.10 Femtoliter Standard Deviation 0.559	-0.01 Femtoliter Standard Deviation 0.695	-0.20 Femtoliter Standard Deviation 0.785
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 14	-0.33 Femtoliter Standard Deviation 2.255	0.35 Femtoliter Standard Deviation 2.379	-0.69 Femtoliter Standard Deviation 2.122	-0.02 Femtoliter Standard Deviation 2.074

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 9	-0.05 Picograms Standard Deviation 0.635	0.27 Picograms Standard Deviation 0.469	-0.06 Picograms Standard Deviation 0.617	0.01 Picograms Standard Deviation 0.486
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 8	-0.25 Picograms Standard Deviation 1.052	-0.08 Picograms Standard Deviation 0.379	-0.18 Picograms Standard Deviation 0.417	0.15 Picograms Standard Deviation 1.042
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 14	-0.15 Picograms Standard Deviation 1.188	0.19 Picograms Standard Deviation 1.186	-0.28 Picograms Standard Deviation 1.073	-0.01 Picograms Standard Deviation 1.113

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated time points to analyze erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Day 9	-0.023 10^12 cells per liter Standard Deviation 0.1546	-0.090 10^12 cells per liter Standard Deviation 0.2291	0.044 10^12 cells per liter Standard Deviation 0.2637	0.004 10^12 cells per liter Standard Deviation 0.2052
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Day 8	-0.049 10^12 cells per liter Standard Deviation 0.2246	0.022 10^12 cells per liter Standard Deviation 0.2160	0.008 10^12 cells per liter Standard Deviation 0.2079	-0.015 10^12 cells per liter Standard Deviation 0.1855
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Day 14	-0.043 10^12 cells per liter Standard Deviation 0.2695	-0.031 10^12 cells per liter Standard Deviation 0.2130	0.081 10^12 cells per liter Standard Deviation 0.2488	-0.031 10^12 cells per liter Standard Deviation 0.1956

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Day 9	72.0 Grams per liter Standard Deviation 3.09	67.9 Grams per liter Standard Deviation 3.83	70.9 Grams per liter Standard Deviation 4.14	69.1 Grams per liter Standard Deviation 4.15
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Day 14	68.2 Grams per liter Standard Deviation 4.26	69.4 Grams per liter Standard Deviation 3.80	70.3 Grams per liter Standard Deviation 5.01	68.8 Grams per liter Standard Deviation 5.09
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Baseline (Day -2)	43.8 Grams per liter Standard Deviation 2.89	44.0 Grams per liter Standard Deviation 3.12	43.6 Grams per liter Standard Deviation 3.18	44.5 Grams per liter Standard Deviation 3.33
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Day 8	41.7 Grams per liter Standard Deviation 2.86	42.0 Grams per liter Standard Deviation 3.39	42.2 Grams per liter Standard Deviation 2.55	42.8 Grams per liter Standard Deviation 2.57
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Day 9	42.7 Grams per liter Standard Deviation 2.83	43.5 Grams per liter Standard Deviation 1.63	44.0 Grams per liter Standard Deviation 3.28	43.5 Grams per liter Standard Deviation 2.59
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Day 14	43.2 Grams per liter Standard Deviation 2.96	42.8 Grams per liter Standard Deviation 2.68	43.9 Grams per liter Standard Deviation 3.20	42.8 Grams per liter Standard Deviation 2.59
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Baseline (Day -2)	26.6 Grams per liter Standard Deviation 4.43	26.0 Grams per liter Standard Deviation 3.77	25.9 Grams per liter Standard Deviation 3.99	26.3 Grams per liter Standard Deviation 3.58
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Day 8	25.1 Grams per liter Standard Deviation 4.04	26.4 Grams per liter Standard Deviation 3.89	25.5 Grams per liter Standard Deviation 4.06	26.4 Grams per liter Standard Deviation 3.51
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Day 9	29.3 Grams per liter Standard Deviation 1.89	24.5 Grams per liter Standard Deviation 3.01	26.9 Grams per liter Standard Deviation 3.89	25.6 Grams per liter Standard Deviation 3.86
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Day 14	25.0 Grams per liter Standard Deviation 3.33	26.6 Grams per liter Standard Deviation 3.88	26.4 Grams per liter Standard Deviation 4.21	26.1 Grams per liter Standard Deviation 3.84
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Baseline (Day -2)	70.4 Grams per liter Standard Deviation 5.22	70.0 Grams per liter Standard Deviation 4.69	69.5 Grams per liter Standard Deviation 4.55	70.7 Grams per liter Standard Deviation 5.02
Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Day 8	66.8 Grams per liter Standard Deviation 4.09	68.4 Grams per liter Standard Deviation 4.70	67.8 Grams per liter Standard Deviation 4.31	69.2 Grams per liter Standard Deviation 4.11

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated timepoints to analyze amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Day 14	23.6 Units per liter Standard Deviation 9.21	26.7 Units per liter Standard Deviation 10.84	24.8 Units per liter Standard Deviation 9.45	26.6 Units per liter Standard Deviation 11.79
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Baseline (Day -2)	55.7 Units per liter Standard Deviation 21.74	55.9 Units per liter Standard Deviation 22.19	58.2 Units per liter Standard Deviation 24.65	56.2 Units per liter Standard Deviation 25.45
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Day 8	52.4 Units per liter Standard Deviation 21.70	59.1 Units per liter Standard Deviation 26.80	53.4 Units per liter Standard Deviation 19.71	57.7 Units per liter Standard Deviation 22.34
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Day 9	66.3 Units per liter Standard Deviation 19.41	49.2 Units per liter Standard Deviation 16.70	61.0 Units per liter Standard Deviation 26.37	44.6 Units per liter Standard Deviation 17.40
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Amylase, Day 14	50.9 Units per liter Standard Deviation 20.92	58.5 Units per liter Standard Deviation 24.58	52.9 Units per liter Standard Deviation 20.11	58.0 Units per liter Standard Deviation 21.02
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Baseline (Day -2),	25.3 Units per liter Standard Deviation 10.98	26.5 Units per liter Standard Deviation 11.59	27.0 Units per liter Standard Deviation 11.06	27.5 Units per liter Standard Deviation 13.93
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Day 8	29.3 Units per liter Standard Deviation 27.50	26.5 Units per liter Standard Deviation 12.22	25.2 Units per liter Standard Deviation 12.39	26.6 Units per liter Standard Deviation 12.87
Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase Lipase, Day 9	28.4 Units per liter Standard Deviation 12.99	23.7 Units per liter Standard Deviation 10.47	28.1 Units per liter Standard Deviation 12.26	22.7 Units per liter Standard Deviation 6.99

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Day 14	-4.1 Micromoles per liter Standard Deviation 30.40	-6.3 Micromoles per liter Standard Deviation 28.01	-4.6 Micromoles per liter Standard Deviation 36.43	-15.7 Micromoles per liter Standard Deviation 26.94
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Day 9	-0.52 Micromoles per liter Standard Deviation 3.082	1.21 Micromoles per liter Standard Deviation 2.806	1.10 Micromoles per liter Standard Deviation 3.561	-0.07 Micromoles per liter Standard Deviation 2.873
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Day 8	-0.03 Micromoles per liter Standard Deviation 5.326	7.07 Micromoles per liter Standard Deviation 7.515	-1.15 Micromoles per liter Standard Deviation 6.209	1.74 Micromoles per liter Standard Deviation 5.394
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Day 9	1.59 Micromoles per liter Standard Deviation 7.022	3.23 Micromoles per liter Standard Deviation 4.312	-0.48 Micromoles per liter Standard Deviation 7.226	2.13 Micromoles per liter Standard Deviation 6.927
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Day 14	0.67 Micromoles per liter Standard Deviation 6.049	2.71 Micromoles per liter Standard Deviation 5.478	-0.37 Micromoles per liter Standard Deviation 5.890	1.30 Micromoles per liter Standard Deviation 4.255
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Day 8	-6.0 Micromoles per liter Standard Deviation 31.24	2.7 Micromoles per liter Standard Deviation 23.18	-8.1 Micromoles per liter Standard Deviation 27.06	-23.4 Micromoles per liter Standard Deviation 26.58
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Day 9	-4.7 Micromoles per liter Standard Deviation 12.04	13.4 Micromoles per liter Standard Deviation 24.46	17.7 Micromoles per liter Standard Deviation 16.53	-17.1 Micromoles per liter Standard Deviation 24.15
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Day 8	-2.15 Micromoles per liter Standard Deviation 3.823	-1.16 Micromoles per liter Standard Deviation 2.946	-0.17 Micromoles per liter Standard Deviation 3.235	-0.06 Micromoles per liter Standard Deviation 3.984
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Day 14	-0.65 Micromoles per liter Standard Deviation 2.832	1.36 Micromoles per liter Standard Deviation 3.546	1.54 Micromoles per liter Standard Deviation 3.563	0.01 Micromoles per liter Standard Deviation 3.193
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Day 8	-0.33 Micromoles per liter Standard Deviation 0.621	-0.17 Micromoles per liter Standard Deviation 0.581	-0.06 Micromoles per liter Standard Deviation 0.578	0.14 Micromoles per liter Standard Deviation 0.821
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Day 9	-0.12 Micromoles per liter Standard Deviation 0.512	0.15 Micromoles per liter Standard Deviation 0.589	0.19 Micromoles per liter Standard Deviation 0.625	0.22 Micromoles per liter Standard Deviation 0.503
Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Day 14	-0.12 Micromoles per liter Standard Deviation 0.492	0.14 Micromoles per liter Standard Deviation 0.582	0.19 Micromoles per liter Standard Deviation 0.618	0.00 Micromoles per liter Standard Deviation 0.582

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated timepoints to analyze albumin, globulin, and total protein. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Day 8	-3.1 Grams per liter Standard Deviation 4.31	-2.1 Grams per liter Standard Deviation 3.86	-1.8 Grams per liter Standard Deviation 3.38	-2.2 Grams per liter Standard Deviation 3.45
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Day 8	-2.5 Grams per liter Standard Deviation 3.00	-2.0 Grams per liter Standard Deviation 2.58	-1.6 Grams per liter Standard Deviation 1.89	-2.2 Grams per liter Standard Deviation 2.05
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Day 9	0.4 Grams per liter Standard Deviation 2.07	-0.5 Grams per liter Standard Deviation 3.14	1.1 Grams per liter Standard Deviation 2.15	0.7 Grams per liter Standard Deviation 2.45
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Albumin, Day 14	-0.9 Grams per liter Standard Deviation 2.82	-1.2 Grams per liter Standard Deviation 2.32	0.1 Grams per liter Standard Deviation 2.72	-2.3 Grams per liter Standard Deviation 2.21
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Day 8	-0.6 Grams per liter Standard Deviation 1.80	-0.1 Grams per liter Standard Deviation 1.96	-0.2 Grams per liter Standard Deviation 2.12	-0.1 Grams per liter Standard Deviation 1.96
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Day 9	0.0 Grams per liter Standard Deviation 2.11	-0.5 Grams per liter Standard Deviation 2.38	0.4 Grams per liter Standard Deviation 1.94	0.0 Grams per liter Standard Deviation 1.63
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Globulin, Day 14	-0.4 Grams per liter Standard Deviation 1.99	0.1 Grams per liter Standard Deviation 1.88	0.6 Grams per liter Standard Deviation 1.70	-0.2 Grams per liter Standard Deviation 1.46
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Day 9	0.4 Grams per liter Standard Deviation 3.86	-0.9 Grams per liter Standard Deviation 5.19	1.6 Grams per liter Standard Deviation 3.91	0.7 Grams per liter Standard Deviation 3.95
Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein Total protein, Day 14	-1.3 Grams per liter Standard Deviation 4.32	-1.1 Grams per liter Standard Deviation 3.41	0.7 Grams per liter Standard Deviation 4.05	-2.6 Grams per liter Standard Deviation 2.98

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Blood samples were collected at indicated timepoints to analyze amylase, lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Amylase, Day 8	-0.8 Units per liter Standard Deviation 9.90	-0.1 Units per liter Standard Deviation 11.55	-3.6 Units per liter Standard Deviation 11.84	-2.5 Units per liter Standard Deviation 10.69
Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Amylase, Day 9	3.1 Units per liter Standard Deviation 7.87	2.1 Units per liter Standard Deviation 7.61	-1.0 Units per liter Standard Deviation 7.09	0.4 Units per liter Standard Deviation 2.84
Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Amylase, Day 14	-2.3 Units per liter Standard Deviation 7.59	-0.7 Units per liter Standard Deviation 9.91	-4.1 Units per liter Standard Deviation 16.30	-2.3 Units per liter Standard Deviation 11.00
Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Lipase, Day 8	4.4 Units per liter Standard Deviation 27.20	-0.7 Units per liter Standard Deviation 7.57	-1.5 Units per liter Standard Deviation 9.36	-3.0 Units per liter Standard Deviation 9.31
Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Lipase, Day 9	0.9 Units per liter Standard Deviation 3.63	-0.9 Units per liter Standard Deviation 5.28	0.2 Units per liter Standard Deviation 5.52	1.7 Units per liter Standard Deviation 3.86
Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Lipase, Day 14	-1.5 Units per liter Standard Deviation 5.66	-0.5 Units per liter Standard Deviation 7.71	-1.8 Units per liter Standard Deviation 8.08	-2.6 Units per liter Standard Deviation 9.97

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Urine samples were collected at indicated time points to analyze the urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity Baseline (Day -2)	1.0152 Ratio Standard Deviation 0.00779	1.0153 Ratio Standard Deviation 0.00930	1.0167 Ratio Standard Deviation 0.00894	1.0161 Ratio Standard Deviation 0.00850
Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity Day 8	1.0180 Ratio Standard Deviation 0.00761	1.0164 Ratio Standard Deviation 0.00846	1.0179 Ratio Standard Deviation 0.00767	1.0188 Ratio Standard Deviation 0.00590
Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity Day 9	1.0189 Ratio Standard Deviation 0.00973	1.0219 Ratio Standard Deviation 0.00762	1.0179 Ratio Standard Deviation 0.00595	1.0136 Ratio Standard Deviation 0.00840
Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity Day 14	1.0165 Ratio Standard Deviation 0.00779	1.0170 Ratio Standard Deviation 0.00804	1.0165 Ratio Standard Deviation 0.00782	1.0175 Ratio Standard Deviation 0.00872

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Urine samples were collected at indicated time points to analyze the urine pH by dipstick test. The dipstick test gives results in a semi-quantitative manner indicating proportional concentrations in the urine sample. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Urinalysis Parameter: pH Day 9	5.75 pH Standard Deviation 0.264	5.91 pH Standard Deviation 0.625	6.06 pH Standard Deviation 0.527	6.20 pH Standard Deviation 0.483
Part 2: Absolute Values for Urinalysis Parameter: pH Baseline (Day -2)	6.10 pH Standard Deviation 0.386	6.19 pH Standard Deviation 0.574	6.09 pH Standard Deviation 0.479	6.13 pH Standard Deviation 0.596
Part 2: Absolute Values for Urinalysis Parameter: pH Day 8	5.90 pH Standard Deviation 0.327	5.88 pH Standard Deviation 0.415	5.98 pH Standard Deviation 0.302	6.02 pH Standard Deviation 0.278
Part 2: Absolute Values for Urinalysis Parameter: pH Day 14	6.00 pH Standard Deviation 0.491	6.00 pH Standard Deviation 0.378	6.13 pH Standard Deviation 0.447	6.12 pH Standard Deviation 0.475

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Urine samples were collected at indicated time points to analyze the urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 8	0.0034 Ratio Standard Deviation 0.00849	0.0030 Ratio Standard Deviation 0.00875	0.0019 Ratio Standard Deviation 0.00727	0.0026 Ratio Standard Deviation 0.01037
Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 9	0.0015 Ratio Standard Deviation 0.00619	0.0015 Ratio Standard Deviation 0.00708	-0.0011 Ratio Standard Deviation 0.01080	-0.0020 Ratio Standard Deviation 0.00850
Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 14	0.0022 Ratio Standard Deviation 0.00747	0.0037 Ratio Standard Deviation 0.00838	0.0005 Ratio Standard Deviation 0.00922	0.0016 Ratio Standard Deviation 0.01055

SECONDARY outcome

Timeframe: Baseline (Day -2), Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at specified time points were analyzed.

Urine samples were collected at indicated time points to analyze the urine pH by dipstick test. The dipstick test gives results in a semi-quantitative manner indicating proportional concentrations in the urine sample. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Urinalysis Parameter: pH Day 8	-0.19 pH Standard Deviation 0.441	-0.33 pH Standard Deviation 0.539	-0.08 pH Standard Deviation 0.389	-0.18 pH Standard Deviation 0.676
Part 2: Change From Baseline in Urinalysis Parameter: pH Day 9	-0.35 pH Standard Deviation 0.337	-0.23 pH Standard Deviation 0.344	-0.11 pH Standard Deviation 0.546	0.30 pH Standard Deviation 0.350
Part 2: Change From Baseline in Urinalysis Parameter: pH Day 14	-0.13 pH Standard Deviation 0.490	-0.21 pH Standard Deviation 0.590	0.06 pH Standard Deviation 0.442	-0.09 pH Standard Deviation 0.708

SECONDARY outcome

Timeframe: Baseline(Day-2), Day1: 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours; Day 2: 24 Hours, Day 4: 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, Day 5: 24 Hours; Day 7: 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours; Day 8: 24 Hours; Day 9 and Day 14

Population: Safety Population.

A 12-lead ECG was recorded with the participant in a supine position. 12-lead ECGs were obtained by using an automated ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with clinically significant abnormal 12-Lead ECG findings has reported.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 1: 6 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Baseline (Day -2)	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 1: 1 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 1: 2 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 1: 3 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 1: 4 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 2: 24 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 4: 1 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 4: 2 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 4: 3 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 4: 4 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 4: 6 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 5: 24 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 7: 1 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 7: 2 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 7: 3 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 7: 4 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 7: 6 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 8: 24 Hours	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 9	0 Participants	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings Day 14	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, and Day 14

Population: Safety Population. Only those participants with data available at the indicated time points were analyzed.

SBP and DBP were measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.

Outcome measures
Measure	Part 1: GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day 7, Predose	2.7 Milliseconds Interval 1.01 to 4.46	3.3 Milliseconds Interval 1.61 to 5.01	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 0.5 Hour Post-dose	-1.9 Milliseconds Interval -3.75 to 0.02	-2.1 Milliseconds Interval -3.98 to -0.19	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day 7, 1 Hour Post-dose	-0.3 Milliseconds Interval -2.22 to 1.68	-1.1 Milliseconds Interval -3.04 to 0.88	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day 7, 2 Hour Post-dose	-3.9 Milliseconds Interval -6.09 to -1.76	1.7 Milliseconds Interval -0.53 to 3.85	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day 7, 3 Hour Post-dose	-4.3 Milliseconds Interval -6.48 to -2.18	3.6 Milliseconds Interval 1.44 to 5.77	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 3.5 Hour Post-dose	-4.4 Milliseconds Interval -6.33 to -2.38	4.5 Milliseconds Interval 2.55 to 6.5	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 4 Hour Post-dose	-3.0 Milliseconds Interval -4.88 to -1.14	5.6 Milliseconds Interval 3.75 to 7.5	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 4.5 Hour Post-dose	-2.6 Milliseconds Interval -4.57 to -0.53	5.9 Milliseconds Interval 3.83 to 7.87	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 5 Hour Post-dose	-1.3 Milliseconds Interval -3.19 to 0.64	6.9 Milliseconds Interval 4.97 to 8.8	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 6 Hour Post-dose	-2.9 Milliseconds Interval -5.25 to -0.52	5.3 Milliseconds Interval 2.98 to 7.69	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 8 Hour Post-dose	-7.7 Milliseconds Interval -9.67 to -5.7	-0.8 Milliseconds Interval -2.72 to 1.21	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 10 Hour Post-dose	-4.2 Milliseconds Interval -6.05 to -2.4	2.6 Milliseconds Interval 0.76 to 4.37	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 12 Hour Post-dose	-2.0 Milliseconds Interval -4.12 to 0.1	3.3 Milliseconds Interval 1.19 to 5.33	—	—
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm Day7, 24 Hour Post-dose	-0.6 Milliseconds Interval -2.57 to 1.39	6.2 Milliseconds Interval 4.28 to 8.21	—	—

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part 1: Placebo n=2 participants at risk Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.	Part 1: GSK3640254 500 mg n=6 participants at risk Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=42 participants at risk Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: Moxifloxacin 400 mg n=40 participants at risk Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 100 mg n=40 participants at risk Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 participants at risk Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Nervous system disorders Headache	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Nervous system disorders Presyncope	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Immune system disorders Seasonal allergy	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Renal and urinary disorders Urinary hesitation	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Reproductive system and breast disorders Menstruation irregular	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Back pain	50.0% 1/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	16.7% 1/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Muscle spasms	50.0% 1/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Nervous system disorders Somnolence	50.0% 1/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	15.0% 6/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Gastrointestinal disorders Nausea	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	5.0% 2/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Gastrointestinal disorders Abdominal distension	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
General disorders Fatigue	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Gastrointestinal disorders Haemorrhoids	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
General disorders Medical device site dermatitis	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	5.0% 2/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
General disorders Vessel puncture site pain	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
General disorders Chills	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Acne	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	5.0% 2/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Infections and infestations Coronavirus infection	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Infections and infestations Nasopharyngitis	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.4% 1/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Infections and infestations Trichomoniasis	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.
Nervous system disorders Dizziness	0.00% 0/2 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/6 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/42 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	2.5% 1/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.	0.00% 0/40 • All-cause mortality, Serious adverse events (SAEs), and non-SAEs were collected up to Day 9 in Part 1 and up to Day 51 in Part 2 of the study All cause mortality, SAEs and non-SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study intervention. AE data has been presented treatment-wise and part-wise.

Additional Information

GSK Response Center

ViiV Healthcare

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Baseline (Day -2)	2.520 10^9 cells per liter Standard Deviation 0.2828	1.822 10^9 cells per liter Standard Deviation 0.6201	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Day 3	4.300 10^9 cells per liter Standard Deviation 3.8608	3.015 10^9 cells per liter Standard Deviation 1.0263	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Day 7	4.205 10^9 cells per liter Standard Deviation 3.6557	3.278 10^9 cells per liter Standard Deviation 0.8286	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 9	239.0 10^9 cells per liter Standard Deviation 82.02	269.8 10^9 cells per liter Standard Deviation 74.88	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Baseline (Day -2)	0.375 10^9 cells per liter Standard Deviation 0.0071	0.137 10^9 cells per liter Standard Deviation 0.1166	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Day 3	0.350 10^9 cells per liter Standard Deviation 0.1838	0.115 10^9 cells per liter Standard Deviation 0.0794	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Day 7	0.345 10^9 cells per liter Standard Deviation 0.2758	0.102 10^9 cells per liter Standard Deviation 0.0804	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Baseline (Day -2)	0.070 10^9 cells per liter Standard Deviation 0.0424	0.057 10^9 cells per liter Standard Deviation 0.0163	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Day 3	0.065 10^9 cells per liter Standard Deviation 0.0212	0.053 10^9 cells per liter Standard Deviation 0.0186	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Day 7	0.065 10^9 cells per liter Standard Deviation 0.0212	0.048 10^9 cells per liter Standard Deviation 0.0160	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Day 9	0.060 10^9 cells per liter Standard Deviation 0.0000	0.065 10^9 cells per liter Standard Deviation 0.0176	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Day 9	0.330 10^9 cells per liter Standard Deviation 0.2546	0.097 10^9 cells per liter Standard Deviation 0.0833	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Day 3	2.715 10^9 cells per liter Standard Deviation 0.5020	1.657 10^9 cells per liter Standard Deviation 0.5352	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Day 7	2.515 10^9 cells per liter Standard Deviation 0.1202	1.668 10^9 cells per liter Standard Deviation 0.5780	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Day 9	2.100 10^9 cells per liter Standard Deviation 0.0990	1.935 10^9 cells per liter Standard Deviation 0.7973	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Baseline (Day -2)	0.550 10^9 cells per liter Standard Deviation 0.1414	0.537 10^9 cells per liter Standard Deviation 0.1878	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Day 3	0.570 10^9 cells per liter Standard Deviation 0.1980	0.462 10^9 cells per liter Standard Deviation 0.1253	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Day 7	0.525 10^9 cells per liter Standard Deviation 0.0919	0.490 10^9 cells per liter Standard Deviation 0.1685	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Day 9	0.490 10^9 cells per liter Standard Deviation 0.1980	0.508 10^9 cells per liter Standard Deviation 0.1411	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Baseline (Day -2)	4.010 10^9 cells per liter Standard Deviation 3.3375	3.910 10^9 cells per liter Standard Deviation 0.4029	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Day 9	5.215 10^9 cells per liter Standard Deviation 5.1831	3.168 10^9 cells per liter Standard Deviation 0.8168	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Baseline (Day -2)	228.0 10^9 cells per liter Standard Deviation 50.91	266.5 10^9 cells per liter Standard Deviation 83.32	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 3	233.0 10^9 cells per liter Standard Deviation 59.40	264.2 10^9 cells per liter Standard Deviation 75.68	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 7	243.5 10^9 cells per liter Standard Deviation 68.59	280.0 10^9 cells per liter Standard Deviation 72.09	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Baseline (Day -2)	7.35 10^9 cells per liter Standard Deviation 3.606	6.47 10^9 cells per liter Standard Deviation 1.025	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Day 3	8.00 10^9 cells per liter Standard Deviation 4.384	5.30 10^9 cells per liter Standard Deviation 1.499	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Day 7	7.65 10^9 cells per liter Standard Deviation 3.606	5.58 10^9 cells per liter Standard Deviation 1.466	—	—
Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Day 9	8.15 10^9 cells per liter Standard Deviation 5.020	5.75 10^9 cells per liter Standard Deviation 1.738	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 3	5.0 10^9 cells per liter Standard Deviation 8.49	-2.3 10^9 cells per liter Standard Deviation 17.68	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Day 9	-0.060 10^9 cells per liter Standard Deviation 0.0566	-0.028 10^9 cells per liter Standard Deviation 0.0755	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Day 3	0.290 10^9 cells per liter Standard Deviation 0.5233	-0.895 10^9 cells per liter Standard Deviation 0.7988	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Day 7	0.195 10^9 cells per liter Standard Deviation 0.3182	-0.632 10^9 cells per liter Standard Deviation 0.5515	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Day 9	1.205 10^9 cells per liter Standard Deviation 1.8455	-0.742 10^9 cells per liter Standard Deviation 0.8588	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 7	15.5 10^9 cells per liter Standard Deviation 17.68	13.5 10^9 cells per liter Standard Deviation 29.49	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 9	11.0 10^9 cells per liter Standard Deviation 31.11	3.3 10^9 cells per liter Standard Deviation 36.74	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Day 3	0.65 10^9 cells per liter Standard Deviation 0.778	-1.17 10^9 cells per liter Standard Deviation 0.942	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Day 3	-0.005 10^9 cells per liter Standard Deviation 0.0212	-0.003 10^9 cells per liter Standard Deviation 0.0137	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Day 7	-0.005 10^9 cells per liter Standard Deviation 0.0212	-0.008 10^9 cells per liter Standard Deviation 0.0160	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Day 7	0.30 10^9 cells per liter Standard Deviation 0.000	-0.88 10^9 cells per liter Standard Deviation 0.818	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils, Day 9	-0.010 10^9 cells per liter Standard Deviation 0.0424	0.008 10^9 cells per liter Standard Deviation 0.0098	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Day 9	0.80 10^9 cells per liter Standard Deviation 1.414	-0.72 10^9 cells per liter Standard Deviation 1.011	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Day 3	-0.025 10^9 cells per liter Standard Deviation 0.1909	-0.022 10^9 cells per liter Standard Deviation 0.0462	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Day 7	-0.030 10^9 cells per liter Standard Deviation 0.2828	-0.035 10^9 cells per liter Standard Deviation 0.0497	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils, Day 9	-0.045 10^9 cells per liter Standard Deviation 0.2616	-0.040 10^9 cells per liter Standard Deviation 0.0559	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Day 3	0.195 10^9 cells per liter Standard Deviation 0.2192	-0.165 10^9 cells per liter Standard Deviation 0.2870	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Day 7	-0.005 10^9 cells per liter Standard Deviation 0.1626	-0.153 10^9 cells per liter Standard Deviation 0.3222	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes, Day 9	-0.420 10^9 cells per liter Standard Deviation 0.3818	0.113 10^9 cells per liter Standard Deviation 0.2908	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Day 3	0.020 10^9 cells per liter Standard Deviation 0.0566	-0.075 10^9 cells per liter Standard Deviation 0.0885	—	—
Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes, Day 7	-0.025 10^9 cells per liter Standard Deviation 0.0495	-0.047 10^9 cells per liter Standard Deviation 0.1111	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Glucose, Day 9	4.635 Millimoles per liter Standard Deviation 0.5162	4.605 Millimoles per liter Standard Deviation 0.2660	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Cholesterol, Day 3	5.390 Millimoles per liter Standard Deviation 1.1738	4.370 Millimoles per liter Standard Deviation 0.5531	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Cholesterol, Day 7	5.180 Millimoles per liter Standard Deviation 1.1031	4.413 Millimoles per liter Standard Deviation 0.7692	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Magnesium, Baseline (Day -2)	0.760 Millimoles per liter Standard Deviation 0.0283	0.767 Millimoles per liter Standard Deviation 0.0413	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Magnesium, Day 9	0.800 Millimoles per liter Standard Deviation 0.0283	0.813 Millimoles per liter Standard Deviation 0.0301	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Triglycerides, Day 3	1.205 Millimoles per liter Standard Deviation 0.1909	0.857 Millimoles per liter Standard Deviation 0.2474	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Anion gap, Day 3	11.5 Millimoles per liter Standard Deviation 2.12	9.5 Millimoles per liter Standard Deviation 1.52	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Phosphate, Day 3	1.210 Millimoles per liter Standard Deviation 0.0707	1.238 Millimoles per liter Standard Deviation 0.0519	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Phosphate, Day 9	1.130 Millimoles per liter Standard Deviation 0.0000	1.212 Millimoles per liter Standard Deviation 0.1983	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Potassium, Day 3	4.00 Millimoles per liter Standard Deviation 0.141	4.28 Millimoles per liter Standard Deviation 0.232	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Sodium, Day 3	138.0 Millimoles per liter Standard Deviation 1.41	136.5 Millimoles per liter Standard Deviation 1.05	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Blood Urea Nitrogen, Baseline (Day -2)	4.300 Millimoles per liter Standard Deviation 1.4425	4.482 Millimoles per liter Standard Deviation 1.2674	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Calcium, Baseline (Day -2)	2.440 Millimoles per liter Standard Deviation 0.0566	2.332 Millimoles per liter Standard Deviation 0.0659	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Calcium, Day 3	2.430 Millimoles per liter Standard Deviation 0.0000	2.370 Millimoles per liter Standard Deviation 0.0930	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Glucose, Baseline (Day -2)	5.050 Millimoles per liter Standard Deviation 0.3960	4.682 Millimoles per liter Standard Deviation 0.3788	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Glucose, Day 3	4.495 Millimoles per liter Standard Deviation 0.2333	4.745 Millimoles per liter Standard Deviation 0.3566	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Glucose, Day 7	4.465 Millimoles per liter Standard Deviation 0.1202	4.728 Millimoles per liter Standard Deviation 0.3251	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Cholesterol, Baseline (Day-2)	5.025 Millimoles per liter Standard Deviation 0.6576	4.112 Millimoles per liter Standard Deviation 0.6916	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Cholesterol, Day 9	5.000 Millimoles per liter Standard Deviation 0.9192	4.205 Millimoles per liter Standard Deviation 0.8352	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Magnesium, Day 3	0.800 Millimoles per liter Standard Deviation 0.0849	0.787 Millimoles per liter Standard Deviation 0.0301	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Magnesium, Day 7	0.800 Millimoles per liter Standard Deviation 0.0283	0.787 Millimoles per liter Standard Deviation 0.0393	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Triglycerides, Baseline (Day -2)	1.295 Millimoles per liter Standard Deviation 0.8839	0.763 Millimoles per liter Standard Deviation 0.2595	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Triglycerides, Day 7	1.005 Millimoles per liter Standard Deviation 0.2192	0.658 Millimoles per liter Standard Deviation 0.2024	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Triglycerides, Day 9	0.965 Millimoles per liter Standard Deviation 0.1626	0.615 Millimoles per liter Standard Deviation 0.1946	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Anion gap, Baseline (Day-2)	12.5 Millimoles per liter Standard Deviation 0.71	10.3 Millimoles per liter Standard Deviation 1.51	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Anion gap, Day 7	10.0 Millimoles per liter Standard Deviation 0.00	10.3 Millimoles per liter Standard Deviation 1.03	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Anion gap, Day 9	11.0 Millimoles per liter Standard Deviation 1.41	10.7 Millimoles per liter Standard Deviation 1.75	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Calcium, Day 7	2.440 Millimoles per liter Standard Deviation 0.0566	2.408 Millimoles per liter Standard Deviation 0.1114	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Calcium, Day 9	2.390 Millimoles per liter Standard Deviation 0.0566	2.337 Millimoles per liter Standard Deviation 0.0843	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Carbon dioxide, Baseline (Day -2)	29.0 Millimoles per liter Standard Deviation 1.41	28.7 Millimoles per liter Standard Deviation 1.75	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Carbon dioxide, Day 3	30.0 Millimoles per liter Standard Deviation 1.41	28.7 Millimoles per liter Standard Deviation 2.16	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Carbon dioxide, Day 7	30.5 Millimoles per liter Standard Deviation 0.71	29.2 Millimoles per liter Standard Deviation 1.60	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Carbon dioxide, Day 9	30.0 Millimoles per liter Standard Deviation 0.00	29.3 Millimoles per liter Standard Deviation 2.25	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Chloride, Baseline (Day -2)	101.0 Millimoles per liter Standard Deviation 2.83	103.7 Millimoles per liter Standard Deviation 1.63	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Chloride, Day 3	100.5 Millimoles per liter Standard Deviation 2.12	102.7 Millimoles per liter Standard Deviation 1.75	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Chloride, Day 7	101.5 Millimoles per liter Standard Deviation 0.71	102.2 Millimoles per liter Standard Deviation 1.60	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Chloride, Day 9	102.5 Millimoles per liter Standard Deviation 0.71	103.2 Millimoles per liter Standard Deviation 1.17	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Phosphate, Baseline (Day -2)	1.195 Millimoles per liter Standard Deviation 0.0919	1.142 Millimoles per liter Standard Deviation 0.1443	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Phosphate, Day 7	1.195 Millimoles per liter Standard Deviation 0.0495	1.223 Millimoles per liter Standard Deviation 0.1203	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Potassium, Baseline (Day -2)	4.05 Millimoles per liter Standard Deviation 0.071	4.10 Millimoles per liter Standard Deviation 0.410	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Potassium, Day 7	4.35 Millimoles per liter Standard Deviation 0.071	4.22 Millimoles per liter Standard Deviation 0.133	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Potassium, Day 9	4.05 Millimoles per liter Standard Deviation 0.071	4.20 Millimoles per liter Standard Deviation 0.228	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Sodium, Baseline (Day -2)	138.5 Millimoles per liter Standard Deviation 0.71	138.5 Millimoles per liter Standard Deviation 1.64	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Sodium, Day 7	138.0 Millimoles per liter Standard Deviation 0.00	137.7 Millimoles per liter Standard Deviation 1.51	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Sodium, Day 9	139.5 Millimoles per liter Standard Deviation 2.12	139.0 Millimoles per liter Standard Deviation 0.89	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Blood Urea Nitrogen, Day 3	4.625 Millimoles per liter Standard Deviation 1.2374	4.648 Millimoles per liter Standard Deviation 0.6614	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Blood Urea Nitrogen, Day 7	5.230 Millimoles per liter Standard Deviation 0.7778	4.690 Millimoles per liter Standard Deviation 0.6622	—	—
Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen Blood Urea Nitrogen, Day 9	4.715 Millimoles per liter Standard Deviation 0.4031	4.332 Millimoles per liter Standard Deviation 0.7889	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALP, Day 7	75.0 International units per liter Standard Deviation 26.87	54.8 International units per liter Standard Deviation 16.22	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase AST, Day 3	24.5 International units per liter Standard Deviation 12.02	17.5 International units per liter Standard Deviation 2.35	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase AST, Day 9	18.0 International units per liter Standard Deviation 5.66	17.5 International units per liter Standard Deviation 3.99	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase GGT, Day 3	21.5 International units per liter Standard Deviation 14.85	10.8 International units per liter Standard Deviation 3.37	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase GGT, Day 7	20.0 International units per liter Standard Deviation 14.14	12.0 International units per liter Standard Deviation 3.29	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Creatine kinase, Day 3	64.5 International units per liter Standard Deviation 24.75	91.2 International units per liter Standard Deviation 69.29	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Lactate dehydrogenase, Day 7	142.0 International units per liter Standard Deviation 22.63	115.8 International units per liter Standard Deviation 22.05	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Lactate dehydrogenase, Day 9	133.0 International units per liter Standard Deviation 24.04	114.5 International units per liter Standard Deviation 26.10	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALT, Baseline (Day -2),	33.0 International units per liter Standard Deviation 28.28	19.7 International units per liter Standard Deviation 10.97	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALT, Day 3	37.5 International units per liter Standard Deviation 33.23	16.8 International units per liter Standard Deviation 7.94	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALT, Day 7	33.5 International units per liter Standard Deviation 26.16	17.7 International units per liter Standard Deviation 5.92	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase AST, Baseline (Day -2)	25.0 International units per liter Standard Deviation 9.90	19.8 International units per liter Standard Deviation 6.49	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALT, Day 9	28.5 International units per liter Standard Deviation 23.33	18.2 International units per liter Standard Deviation 8.75	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALP, Baseline (Day -2)	73.0 International units per liter Standard Deviation 22.63	54.3 International units per liter Standard Deviation 26.79	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALP, Day 3	76.5 International units per liter Standard Deviation 23.33	50.0 International units per liter Standard Deviation 15.05	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase ALP, Day 9	75.5 International units per liter Standard Deviation 26.16	54.5 International units per liter Standard Deviation 17.44	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase AST, Day 7	21.5 International units per liter Standard Deviation 7.78	18.0 International units per liter Standard Deviation 2.53	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase GGT, Baseline (Day -2)	21.0 International units per liter Standard Deviation 14.14	11.0 International units per liter Standard Deviation 3.22	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase GGT, Day 9	19.5 International units per liter Standard Deviation 13.44	12.0 International units per liter Standard Deviation 3.69	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Creatine kinase, Baseline (Day -2)	93.0 International units per liter Standard Deviation 50.91	160.7 International units per liter Standard Deviation 124.55	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Creatine kinase, Day 7	71.5 International units per liter Standard Deviation 53.03	71.5 International units per liter Standard Deviation 53.73	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Creatine kinase, Day 9	60.5 International units per liter Standard Deviation 34.65	75.5 International units per liter Standard Deviation 56.79	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Lactate dehydrogenase, Baseline (Day -2)	161.5 International units per liter Standard Deviation 36.06	132.0 International units per liter Standard Deviation 22.04	—	—
Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase Lactate dehydrogenase, Day 3	150.0 International units per liter Standard Deviation 46.67	113.3 International units per liter Standard Deviation 22.55	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Direct Bilirubin, Day 7	1.60 Micromoles per liter Standard Deviation 0.141	2.10 Micromoles per liter Standard Deviation 1.016	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Direct Bilirubin, Day 9	1.55 Micromoles per liter Standard Deviation 0.212	2.05 Micromoles per liter Standard Deviation 0.862	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Creatinine, Baseline (Day -2)	89.75 Micromoles per liter Standard Deviation 16.900	74.85 Micromoles per liter Standard Deviation 15.104	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Creatinine, Day 3	83.10 Micromoles per liter Standard Deviation 13.718	72.20 Micromoles per liter Standard Deviation 8.322	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Creatinine, Day 7	86.60 Micromoles per liter Standard Deviation 14.991	70.13 Micromoles per liter Standard Deviation 8.411	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Creatinine, Day 9	85.30 Micromoles per liter Standard Deviation 10.607	71.00 Micromoles per liter Standard Deviation 8.919	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Urate, Baseline (Day -2)	363.0 Micromoles per liter Standard Deviation 0.00	274.5 Micromoles per liter Standard Deviation 72.37	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Urate, Day 3	351.0 Micromoles per liter Standard Deviation 50.91	259.0 Micromoles per liter Standard Deviation 61.48	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Urate, Day 7	365.5 Micromoles per liter Standard Deviation 54.45	246.0 Micromoles per liter Standard Deviation 60.52	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Urate, Day 9	348.0 Micromoles per liter Standard Deviation 55.15	257.0 Micromoles per liter Standard Deviation 59.67	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Direct Bilirubin, Day 3	1.45 Micromoles per liter Standard Deviation 0.071	1.68 Micromoles per liter Standard Deviation 0.571	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Total Bilirubin, Baseline (Day -2)	5.60 Micromoles per liter Standard Deviation 1.697	7.00 Micromoles per liter Standard Deviation 3.033	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Total Bilirubin, Day 3	8.55 Micromoles per liter Standard Deviation 0.212	9.63 Micromoles per liter Standard Deviation 3.059	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Total Bilirubin, Day 7	8.75 Micromoles per liter Standard Deviation 0.212	11.33 Micromoles per liter Standard Deviation 5.201	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Total Bilirubin, Day 9	7.80 Micromoles per liter Standard Deviation 1.556	10.20 Micromoles per liter Standard Deviation 5.043	—	—
Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin Direct Bilirubin, Baseline (Day -2)	0.95 Micromoles per liter Standard Deviation 0.354	1.42 Micromoles per liter Standard Deviation 0.605	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide, Day 7	1.5 Millimoles per liter Standard Deviation 0.71	0.5 Millimoles per liter Standard Deviation 0.84	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide, Day 3	1.0 Millimoles per liter Standard Deviation 2.83	0.0 Millimoles per liter Standard Deviation 2.00	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose, Day 3	-0.555 Millimoles per liter Standard Deviation 0.6293	0.063 Millimoles per liter Standard Deviation 0.3773	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose, Day 7	-0.585 Millimoles per liter Standard Deviation 0.5162	0.047 Millimoles per liter Standard Deviation 0.2914	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose, Day 9	-0.415 Millimoles per liter Standard Deviation 0.9122	-0.077 Millimoles per liter Standard Deviation 0.3626	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol, Day 3	0.365 Millimoles per liter Standard Deviation 0.5162	0.258 Millimoles per liter Standard Deviation 0.3570	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol, Day 7	0.155 Millimoles per liter Standard Deviation 0.4455	0.302 Millimoles per liter Standard Deviation 0.2662	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol, Day 9	-0.025 Millimoles per liter Standard Deviation 0.2616	0.093 Millimoles per liter Standard Deviation 0.2144	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Magnesium, Day 3	0.040 Millimoles per liter Standard Deviation 0.0566	0.020 Millimoles per liter Standard Deviation 0.0335	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Magnesium, Day 7	0.040 Millimoles per liter Standard Deviation 0.0000	0.020 Millimoles per liter Standard Deviation 0.0551	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Magnesium, Day 9	0.040 Millimoles per liter Standard Deviation 0.0000	0.047 Millimoles per liter Standard Deviation 0.0468	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides, Day 3	-0.090 Millimoles per liter Standard Deviation 0.6930	0.093 Millimoles per liter Standard Deviation 0.2432	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides, Day 7	-0.290 Millimoles per liter Standard Deviation 0.6647	-0.105 Millimoles per liter Standard Deviation 0.2076	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides, Day 9	-0.330 Millimoles per liter Standard Deviation 0.7212	-0.148 Millimoles per liter Standard Deviation 0.2494	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap, Day 3	-1.0 Millimoles per liter Standard Deviation 1.41	-0.8 Millimoles per liter Standard Deviation 1.60	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap, Day 7	-2.5 Millimoles per liter Standard Deviation 0.71	0.0 Millimoles per liter Standard Deviation 1.90	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap, Day 9	-1.5 Millimoles per liter Standard Deviation 2.12	0.3 Millimoles per liter Standard Deviation 2.50	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium, Day 3	-0.010 Millimoles per liter Standard Deviation 0.0566	0.038 Millimoles per liter Standard Deviation 0.0527	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium, Day 7	0.000 Millimoles per liter Standard Deviation 0.1131	0.077 Millimoles per liter Standard Deviation 0.0712	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium, Day 9	-0.050 Millimoles per liter Standard Deviation 0.1131	0.005 Millimoles per liter Standard Deviation 0.0558	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide, Day 9	1.0 Millimoles per liter Standard Deviation 1.41	0.7 Millimoles per liter Standard Deviation 1.86	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride, Day 3	-0.5 Millimoles per liter Standard Deviation 0.71	-1.0 Millimoles per liter Standard Deviation 1.55	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride, Day 7	0.5 Millimoles per liter Standard Deviation 2.12	-1.5 Millimoles per liter Standard Deviation 1.97	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride, Day 9	1.5 Millimoles per liter Standard Deviation 2.12	-0.5 Millimoles per liter Standard Deviation 1.64	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate, Day 3	0.015 Millimoles per liter Standard Deviation 0.1626	0.097 Millimoles per liter Standard Deviation 0.1136	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate, Day 7	0.000 Millimoles per liter Standard Deviation 0.1414	0.082 Millimoles per liter Standard Deviation 0.1625	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate, Day 9	-0.065 Millimoles per liter Standard Deviation 0.0919	0.070 Millimoles per liter Standard Deviation 0.1898	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium, Day 3	-0.05 Millimoles per liter Standard Deviation 0.071	0.18 Millimoles per liter Standard Deviation 0.366	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium, Day 7	0.30 Millimoles per liter Standard Deviation 0.141	0.12 Millimoles per liter Standard Deviation 0.331	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium, Day 9	0.00 Millimoles per liter Standard Deviation 0.000	0.10 Millimoles per liter Standard Deviation 0.363	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium, Day 3	-0.5 Millimoles per liter Standard Deviation 0.71	-2.0 Millimoles per liter Standard Deviation 1.90	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium, Day 7	-0.5 Millimoles per liter Standard Deviation 0.71	-0.8 Millimoles per liter Standard Deviation 2.04	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium, Day 9	1.0 Millimoles per liter Standard Deviation 1.41	0.5 Millimoles per liter Standard Deviation 1.87	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood Urea Nitrogen, Day 3	0.325 Millimoles per liter Standard Deviation 0.2051	0.167 Millimoles per liter Standard Deviation 1.4356	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood Urea Nitrogen, Day 7	0.930 Millimoles per liter Standard Deviation 0.6647	0.208 Millimoles per liter Standard Deviation 1.5113	—	—
Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood Urea Nitrogen, Day 9	0.415 Millimoles per liter Standard Deviation 1.0394	-0.150 Millimoles per liter Standard Deviation 1.2510	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 3	4.5 International units per liter Standard Deviation 4.95	-2.8 International units per liter Standard Deviation 3.71	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 7	0.5 International units per liter Standard Deviation 2.12	-2.0 International units per liter Standard Deviation 9.70	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 9	-4.5 International units per liter Standard Deviation 4.95	-1.5 International units per liter Standard Deviation 12.77	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 3	3.5 International units per liter Standard Deviation 0.71	-4.3 International units per liter Standard Deviation 12.14	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 7	2.0 International units per liter Standard Deviation 4.24	0.5 International units per liter Standard Deviation 12.53	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 9	2.5 International units per liter Standard Deviation 3.54	0.2 International units per liter Standard Deviation 10.80	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 3	-0.5 International units per liter Standard Deviation 2.12	-2.3 International units per liter Standard Deviation 5.50	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 7	-3.5 International units per liter Standard Deviation 2.12	-1.8 International units per liter Standard Deviation 7.91	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 9	-7.0 International units per liter Standard Deviation 4.24	-2.3 International units per liter Standard Deviation 8.80	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 3	0.5 International units per liter Standard Deviation 0.71	-0.2 International units per liter Standard Deviation 1.17	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 7	-1.0 International units per liter Standard Deviation 0.00	1.0 International units per liter Standard Deviation 0.89	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 9	-1.5 International units per liter Standard Deviation 0.71	1.0 International units per liter Standard Deviation 0.89	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 3	-28.5 International units per liter Standard Deviation 26.16	-69.5 International units per liter Standard Deviation 104.08	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 7	-21.5 International units per liter Standard Deviation 2.12	-89.2 International units per liter Standard Deviation 121.90	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 9	-32.5 International units per liter Standard Deviation 16.26	-85.2 International units per liter Standard Deviation 127.35	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 3	-11.5 International units per liter Standard Deviation 10.61	-18.7 International units per liter Standard Deviation 9.27	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 7	-19.5 International units per liter Standard Deviation 13.44	-16.2 International units per liter Standard Deviation 9.99	—	—
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 9	-28.5 International units per liter Standard Deviation 12.02	-17.5 International units per liter Standard Deviation 19.41	—	—

Measure	Part 1: GSK3640254 500 mg n=2 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=6 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Baseline (Pre-dose, Day 1)	120.0 Millimeters (mm) of mercury Standard Deviation 1.41	109.2 Millimeters (mm) of mercury Standard Deviation 12.22	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 2	115.5 Millimeters (mm) of mercury Standard Deviation 0.71	103.8 Millimeters (mm) of mercury Standard Deviation 10.42	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 3	123.0 Millimeters (mm) of mercury Standard Deviation 2.83	106.8 Millimeters (mm) of mercury Standard Deviation 9.87	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 4	121.5 Millimeters (mm) of mercury Standard Deviation 17.68	107.5 Millimeters (mm) of mercury Standard Deviation 13.74	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 5	111.5 Millimeters (mm) of mercury Standard Deviation 9.19	105.3 Millimeters (mm) of mercury Standard Deviation 5.20	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 6	114.0 Millimeters (mm) of mercury Standard Deviation 15.56	107.0 Millimeters (mm) of mercury Standard Deviation 6.57	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 7	117.5 Millimeters (mm) of mercury Standard Deviation 4.95	107.7 Millimeters (mm) of mercury Standard Deviation 10.07	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 8	125.0 Millimeters (mm) of mercury Standard Deviation 1.41	109.0 Millimeters (mm) of mercury Standard Deviation 6.48	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 9	127.0 Millimeters (mm) of mercury Standard Deviation 5.66	109.8 Millimeters (mm) of mercury Standard Deviation 7.81	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Baseline (Pre-dose, Day 1)	74.0 Millimeters (mm) of mercury Standard Deviation 4.24	61.5 Millimeters (mm) of mercury Standard Deviation 8.22	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 2	70.5 Millimeters (mm) of mercury Standard Deviation 4.95	59.8 Millimeters (mm) of mercury Standard Deviation 5.74	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 3	76.0 Millimeters (mm) of mercury Standard Deviation 5.66	59.7 Millimeters (mm) of mercury Standard Deviation 3.14	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 4	66.0 Millimeters (mm) of mercury Standard Deviation 14.14	64.0 Millimeters (mm) of mercury Standard Deviation 9.90	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 5	69.5 Millimeters (mm) of mercury Standard Deviation 21.92	62.3 Millimeters (mm) of mercury Standard Deviation 5.57	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 6	65.5 Millimeters (mm) of mercury Standard Deviation 12.02	61.2 Millimeters (mm) of mercury Standard Deviation 4.49	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 7	72.0 Millimeters (mm) of mercury Standard Deviation 11.31	63.7 Millimeters (mm) of mercury Standard Deviation 5.79	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 8	67.0 Millimeters (mm) of mercury Standard Deviation 8.49	64.5 Millimeters (mm) of mercury Standard Deviation 9.65	—	—
Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 9	69.5 Millimeters (mm) of mercury Standard Deviation 9.19	64.7 Millimeters (mm) of mercury Standard Deviation 7.50	—	—

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Baseline (Day -2)	0.035 10^9 cells per liter Standard Deviation 0.0194	0.036 10^9 cells per liter Standard Deviation 0.0228	0.037 10^9 cells per liter Standard Deviation 0.0218	0.031 10^9 cells per liter Standard Deviation 0.0121
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Day 8	0.035 10^9 cells per liter Standard Deviation 0.0228	0.032 10^9 cells per liter Standard Deviation 0.0176	0.030 10^9 cells per liter Standard Deviation 0.0149	0.039 10^9 cells per liter Standard Deviation 0.0157
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Day 9	0.032 10^9 cells per liter Standard Deviation 0.0155	0.036 10^9 cells per liter Standard Deviation 0.0191	0.039 10^9 cells per liter Standard Deviation 0.0145	0.025 10^9 cells per liter Standard Deviation 0.0108
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Day 9	0.167 10^9 cells per liter Standard Deviation 0.0859	0.120 10^9 cells per liter Standard Deviation 0.0754	0.114 10^9 cells per liter Standard Deviation 0.0688	0.081 10^9 cells per liter Standard Deviation 0.0418
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Day 14	0.113 10^9 cells per liter Standard Deviation 0.0765	0.131 10^9 cells per liter Standard Deviation 0.0918	0.126 10^9 cells per liter Standard Deviation 0.0717	0.141 10^9 cells per liter Standard Deviation 0.0737
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Day 8	1.641 10^9 cells per liter Standard Deviation 0.4661	1.605 10^9 cells per liter Standard Deviation 0.4496	1.675 10^9 cells per liter Standard Deviation 0.5013	1.688 10^9 cells per liter Standard Deviation 0.4620
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Day 9	1.603 10^9 cells per liter Standard Deviation 0.2137	1.907 10^9 cells per liter Standard Deviation 0.6142	1.637 10^9 cells per liter Standard Deviation 0.5265	1.540 10^9 cells per liter Standard Deviation 0.5550
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Day 14	1.710 10^9 cells per liter Standard Deviation 0.5906	1.606 10^9 cells per liter Standard Deviation 0.5602	1.705 10^9 cells per liter Standard Deviation 0.4747	1.755 10^9 cells per liter Standard Deviation 0.5892
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Baseline (Day -2)	0.427 10^9 cells per liter Standard Deviation 0.1533	0.442 10^9 cells per liter Standard Deviation 0.1429	0.451 10^9 cells per liter Standard Deviation 0.1588	0.429 10^9 cells per liter Standard Deviation 0.1476
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Day 9	0.485 10^9 cells per liter Standard Deviation 0.1499	0.468 10^9 cells per liter Standard Deviation 0.1376	0.389 10^9 cells per liter Standard Deviation 0.1312	0.350 10^9 cells per liter Standard Deviation 0.1040
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Day 14	0.413 10^9 cells per liter Standard Deviation 0.1474	0.399 10^9 cells per liter Standard Deviation 0.1469	0.431 10^9 cells per liter Standard Deviation 0.1514	0.448 10^9 cells per liter Standard Deviation 0.1402
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils, Baseline (Day -2)	2.842 10^9 cells per liter Standard Deviation 0.9011	2.902 10^9 cells per liter Standard Deviation 0.8438	2.957 10^9 cells per liter Standard Deviation 1.0517	2.829 10^9 cells per liter Standard Deviation 0.8172
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils,Day 8	2.889 10^9 cells per liter Standard Deviation 0.9751	2.671 10^9 cells per liter Standard Deviation 0.8247	2.825 10^9 cells per liter Standard Deviation 0.8364	2.952 10^9 cells per liter Standard Deviation 0.9562
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets,Baseline (Day -2)	233.7 10^9 cells per liter Standard Deviation 42.39	237.1 10^9 cells per liter Standard Deviation 46.09	234.0 10^9 cells per liter Standard Deviation 48.15	230.8 10^9 cells per liter Standard Deviation 48.34
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 8	228.9 10^9 cells per liter Standard Deviation 43.10	226.4 10^9 cells per liter Standard Deviation 43.06	234.8 10^9 cells per liter Standard Deviation 47.94	224.7 10^9 cells per liter Standard Deviation 41.97
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 9	221.4 10^9 cells per liter Standard Deviation 34.16	233.3 10^9 cells per liter Standard Deviation 62.32	225.9 10^9 cells per liter Standard Deviation 52.60	235.4 10^9 cells per liter Standard Deviation 30.80
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes, Baseline (Day -2)	5.12 10^9 cells per liter Standard Deviation 1.205	5.34 10^9 cells per liter Standard Deviation 1.153	5.31 10^9 cells per liter Standard Deviation 1.325	5.08 10^9 cells per liter Standard Deviation 1.092
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes,Day 8	5.10 10^9 cells per liter Standard Deviation 1.223	4.87 10^9 cells per liter Standard Deviation 0.985	5.11 10^9 cells per liter Standard Deviation 1.151	5.32 10^9 cells per liter Standard Deviation 1.172
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes,Day 9	5.27 10^9 cells per liter Standard Deviation 1.125	5.14 10^9 cells per liter Standard Deviation 1.307	4.78 10^9 cells per liter Standard Deviation 1.411	4.53 10^9 cells per liter Standard Deviation 0.850
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes,Day 14	4.97 10^9 cells per liter Standard Deviation 1.184	4.67 10^9 cells per liter Standard Deviation 1.040	5.05 10^9 cells per liter Standard Deviation 1.054	5.14 10^9 cells per liter Standard Deviation 1.023
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 14	231.6 10^9 cells per liter Standard Deviation 48.26	227.1 10^9 cells per liter Standard Deviation 44.07	234.0 10^9 cells per liter Standard Deviation 40.87	226.7 10^9 cells per liter Standard Deviation 46.75
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Day 14	0.033 10^9 cells per liter Standard Deviation 0.0178	0.031 10^9 cells per liter Standard Deviation 0.0161	0.033 10^9 cells per liter Standard Deviation 0.0177	0.040 10^9 cells per liter Standard Deviation 0.0242
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Baseline (Day -2)	0.124 10^9 cells per liter Standard Deviation 0.0775	0.127 10^9 cells per liter Standard Deviation 0.0794	0.135 10^9 cells per liter Standard Deviation 0.0966	0.123 10^9 cells per liter Standard Deviation 0.0716
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Day 8	0.116 10^9 cells per liter Standard Deviation 0.0637	0.136 10^9 cells per liter Standard Deviation 0.0757	0.130 10^9 cells per liter Standard Deviation 0.0797	0.135 10^9 cells per liter Standard Deviation 0.0725
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Baseline (Day -2)	1.694 10^9 cells per liter Standard Deviation 0.5355	1.830 10^9 cells per liter Standard Deviation 0.5683	1.736 10^9 cells per liter Standard Deviation 0.5498	1.677 10^9 cells per liter Standard Deviation 0.4789
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Day 8	0.426 10^9 cells per liter Standard Deviation 0.1090	0.436 10^9 cells per liter Standard Deviation 0.1518	0.456 10^9 cells per liter Standard Deviation 0.1521	0.501 10^9 cells per liter Standard Deviation 0.1609
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils,Day 9	2.990 10^9 cells per liter Standard Deviation 0.9534	2.618 10^9 cells per liter Standard Deviation 0.8351	2.619 10^9 cells per liter Standard Deviation 1.1073	2.530 10^9 cells per liter Standard Deviation 0.5010
Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils,Day 14	2.712 10^9 cells per liter Standard Deviation 0.8786	2.506 10^9 cells per liter Standard Deviation 0.7270	2.758 10^9 cells per liter Standard Deviation 0.8062	2.750 10^9 cells per liter Standard Deviation 0.7833

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Day 8	-0.002 10^9 cells per liter Standard Deviation 0.0141	-0.003 10^9 cells per liter Standard Deviation 0.0111	-0.004 10^9 cells per liter Standard Deviation 0.0088	0.005 10^9 cells per liter Standard Deviation 0.0107
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Day 9	0.002 10^9 cells per liter Standard Deviation 0.0123	-0.003 10^9 cells per liter Standard Deviation 0.0101	-0.010 10^9 cells per liter Standard Deviation 0.0240	0.002 10^9 cells per liter Standard Deviation 0.0103
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Basophils,Day 14	-0.005 10^9 cells per liter Standard Deviation 0.0178	-0.004 10^9 cells per liter Standard Deviation 0.0105	-0.001 10^9 cells per liter Standard Deviation 0.0116	0.007 10^9 cells per liter Standard Deviation 0.0245
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Day 8	0.002 10^9 cells per liter Standard Deviation 0.0363	0.007 10^9 cells per liter Standard Deviation 0.0405	-0.008 10^9 cells per liter Standard Deviation 0.0525	-0.001 10^9 cells per liter Standard Deviation 0.0367
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Day 9	0.008 10^9 cells per liter Standard Deviation 0.0339	-0.004 10^9 cells per liter Standard Deviation 0.0347	-0.011 10^9 cells per liter Standard Deviation 0.0285	-0.002 10^9 cells per liter Standard Deviation 0.0204
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Eosinophils,Day 14	-0.004 10^9 cells per liter Standard Deviation 0.0382	0.002 10^9 cells per liter Standard Deviation 0.0641	-0.012 10^9 cells per liter Standard Deviation 0.0528	0.006 10^9 cells per liter Standard Deviation 0.0507
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Day 8	-0.129 10^9 cells per liter Standard Deviation 0.3091	-0.161 10^9 cells per liter Standard Deviation 0.3238	-0.071 10^9 cells per liter Standard Deviation 0.3535	-0.039 10^9 cells per liter Standard Deviation 0.2684
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Day 9	0.122 10^9 cells per liter Standard Deviation 0.1852	-0.092 10^9 cells per liter Standard Deviation 0.3865	-0.067 10^9 cells per liter Standard Deviation 0.2649	0.015 10^9 cells per liter Standard Deviation 0.2089
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 8	-7.4 10^9 cells per liter Standard Deviation 23.57	-10.8 10^9 cells per liter Standard Deviation 30.25	-2.2 10^9 cells per liter Standard Deviation 28.56	-4.5 10^9 cells per liter Standard Deviation 24.10
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Lymphocytes,Day 14	-0.066 10^9 cells per liter Standard Deviation 0.2859	-0.160 10^9 cells per liter Standard Deviation 0.2649	-0.041 10^9 cells per liter Standard Deviation 0.3457	0.014 10^9 cells per liter Standard Deviation 0.3589
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Day 8	0.001 10^9 cells per liter Standard Deviation 0.1206	0.014 10^9 cells per liter Standard Deviation 0.0900	-0.015 10^9 cells per liter Standard Deviation 0.1119	0.034 10^9 cells per liter Standard Deviation 0.1148
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Day 9	0.047 10^9 cells per liter Standard Deviation 0.0638	-0.030 10^9 cells per liter Standard Deviation 0.1627	0.010 10^9 cells per liter Standard Deviation 0.0332	0.038 10^9 cells per liter Standard Deviation 0.0382
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Monocytes,Day 14	-0.015 10^9 cells per liter Standard Deviation 0.1347	-0.022 10^9 cells per liter Standard Deviation 0.1413	-0.040 10^9 cells per liter Standard Deviation 0.0967	-0.022 10^9 cells per liter Standard Deviation 0.1388
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils,Day 8	0.018 10^9 cells per liter Standard Deviation 0.8722	-0.272 10^9 cells per liter Standard Deviation 0.6668	-0.319 10^9 cells per liter Standard Deviation 0.7755	-0.022 10^9 cells per liter Standard Deviation 0.7040
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils,Day 9	0.332 10^9 cells per liter Standard Deviation 0.3485	-0.174 10^9 cells per liter Standard Deviation 0.8246	0.306 10^9 cells per liter Standard Deviation 0.4508	0.136 10^9 cells per liter Standard Deviation 0.4495
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Neutrophils,Day 14	-0.155 10^9 cells per liter Standard Deviation 0.5886	-0.437 10^9 cells per liter Standard Deviation 0.7038	-0.386 10^9 cells per liter Standard Deviation 0.6994	-0.262 10^9 cells per liter Standard Deviation 0.5618
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 9	-8.4 10^9 cells per liter Standard Deviation 21.44	-3.5 10^9 cells per liter Standard Deviation 22.10	0.7 10^9 cells per liter Standard Deviation 25.99	7.9 10^9 cells per liter Standard Deviation 28.29
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Platelets, Day 14	-3.2 10^9 cells per liter Standard Deviation 34.31	-10.1 10^9 cells per liter Standard Deviation 31.76	-2.5 10^9 cells per liter Standard Deviation 31.02	-6.7 10^9 cells per liter Standard Deviation 28.80
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes,Day 8	-0.11 10^9 cells per liter Standard Deviation 1.122	-0.42 10^9 cells per liter Standard Deviation 0.858	-0.41 10^9 cells per liter Standard Deviation 0.943	-0.01 10^9 cells per liter Standard Deviation 0.837
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes,Day 9	0.50 10^9 cells per liter Standard Deviation 0.406	-0.32 10^9 cells per liter Standard Deviation 1.138	0.20 10^9 cells per liter Standard Deviation 0.505	0.21 10^9 cells per liter Standard Deviation 0.626
Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Leukocytes,Day 14	-0.24 10^9 cells per liter Standard Deviation 0.669	-0.63 10^9 cells per liter Standard Deviation 0.864	-0.47 10^9 cells per liter Standard Deviation 0.856	-0.24 10^9 cells per liter Standard Deviation 0.721

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactatedehydrogenase, Baseline(Day-2)	119.9 International units per liter Standard Deviation 21.33	122.8 International units per liter Standard Deviation 21.04	119.6 International units per liter Standard Deviation 18.16	121.2 International units per liter Standard Deviation 24.03
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 8	107.5 International units per liter Standard Deviation 18.24	111.8 International units per liter Standard Deviation 19.37	108.0 International units per liter Standard Deviation 17.13	113.5 International units per liter Standard Deviation 16.87
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 9	124.0 International units per liter Standard Deviation 20.88	107.4 International units per liter Standard Deviation 20.66	118.2 International units per liter Standard Deviation 16.69	108.1 International units per liter Standard Deviation 17.01
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 14	113.4 International units per liter Standard Deviation 17.68	113.5 International units per liter Standard Deviation 17.09	116.6 International units per liter Standard Deviation 18.19	118.8 International units per liter Standard Deviation 20.87
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Baseline (Day -2)	18.3 International units per liter Standard Deviation 10.92	16.8 International units per liter Standard Deviation 10.26	17.5 International units per liter Standard Deviation 10.40	16.3 International units per liter Standard Deviation 9.35
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 8	14.0 International units per liter Standard Deviation 7.46	17.2 International units per liter Standard Deviation 9.80	15.7 International units per liter Standard Deviation 10.63	19.5 International units per liter Standard Deviation 11.46
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 9	26.6 International units per liter Standard Deviation 16.04	12.5 International units per liter Standard Deviation 9.50	14.2 International units per liter Standard Deviation 4.29	16.4 International units per liter Standard Deviation 8.69
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 14	13.8 International units per liter Standard Deviation 6.38	18.7 International units per liter Standard Deviation 12.07	16.6 International units per liter Standard Deviation 11.05	19.0 International units per liter Standard Deviation 11.34
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Baseline (Day -2)	58.7 International units per liter Standard Deviation 13.67	58.3 International units per liter Standard Deviation 13.52	58.0 International units per liter Standard Deviation 13.82	58.9 International units per liter Standard Deviation 14.23
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 8	56.8 International units per liter Standard Deviation 11.95	55.6 International units per liter Standard Deviation 12.06	57.1 International units per liter Standard Deviation 12.81	59.6 International units per liter Standard Deviation 13.52
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 9	56.1 International units per liter Standard Deviation 15.32	63.5 International units per liter Standard Deviation 15.28	58.9 International units per liter Standard Deviation 12.64	53.0 International units per liter Standard Deviation 8.03
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 14	56.7 International units per liter Standard Deviation 13.21	55.1 International units per liter Standard Deviation 10.80	58.8 International units per liter Standard Deviation 13.98	59.4 International units per liter Standard Deviation 14.15
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Baseline (Day -2)	15.8 International units per liter Standard Deviation 4.73	15.5 International units per liter Standard Deviation 4.56	15.5 International units per liter Standard Deviation 3.78	15.3 International units per liter Standard Deviation 3.88
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 8	14.0 International units per liter Standard Deviation 3.18	16.0 International units per liter Standard Deviation 9.92	13.7 International units per liter Standard Deviation 3.14	15.6 International units per liter Standard Deviation 4.01
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 9	17.3 International units per liter Standard Deviation 5.14	13.6 International units per liter Standard Deviation 3.26	15.6 International units per liter Standard Deviation 5.05	15.1 International units per liter Standard Deviation 3.75
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 14	14.1 International units per liter Standard Deviation 3.10	15.3 International units per liter Standard Deviation 3.81	14.5 International units per liter Standard Deviation 3.96	15.8 International units per liter Standard Deviation 5.22
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Baseline (Day -2)	16.7 International units per liter Standard Deviation 11.06	17.2 International units per liter Standard Deviation 11.41	16.6 International units per liter Standard Deviation 8.75	16.7 International units per liter Standard Deviation 10.53
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 8	15.0 International units per liter Standard Deviation 11.16	17.9 International units per liter Standard Deviation 11.53	15.2 International units per liter Standard Deviation 7.30	18.7 International units per liter Standard Deviation 10.22
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 9	20.3 International units per liter Standard Deviation 7.63	12.5 International units per liter Standard Deviation 6.56	19.1 International units per liter Standard Deviation 11.61	10.8 International units per liter Standard Deviation 2.44
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 14	14.7 International units per liter Standard Deviation 10.48	17.5 International units per liter Standard Deviation 12.44	15.1 International units per liter Standard Deviation 7.28	17.7 International units per liter Standard Deviation 9.01
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Baseline (Day -2)	103.0 International units per liter Standard Deviation 61.10	120.8 International units per liter Standard Deviation 95.60	112.6 International units per liter Standard Deviation 91.50	117.8 International units per liter Standard Deviation 105.69
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 8	72.8 International units per liter Standard Deviation 42.00	163.9 International units per liter Standard Deviation 428.51	82.5 International units per liter Standard Deviation 48.77	90.3 International units per liter Standard Deviation 51.09
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 9	173.4 International units per liter Standard Deviation 136.99	75.5 International units per liter Standard Deviation 45.25	171.1 International units per liter Standard Deviation 184.31	81.1 International units per liter Standard Deviation 40.14
Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 14	102.1 International units per liter Standard Deviation 113.21	104.9 International units per liter Standard Deviation 63.56	91.7 International units per liter Standard Deviation 55.00	110.1 International units per liter Standard Deviation 76.61

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Baseline (Day -2)	80.51 Micromoles per liter Standard Deviation 13.855	79.38 Micromoles per liter Standard Deviation 14.340	81.86 Micromoles per liter Standard Deviation 14.819	79.83 Micromoles per liter Standard Deviation 14.976
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Day 8	78.45 Micromoles per liter Standard Deviation 16.058	88.55 Micromoles per liter Standard Deviation 16.380	78.38 Micromoles per liter Standard Deviation 15.118	82.01 Micromoles per liter Standard Deviation 16.558
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Day 9	86.89 Micromoles per liter Standard Deviation 13.446	77.07 Micromoles per liter Standard Deviation 17.015	89.38 Micromoles per liter Standard Deviation 14.323	80.63 Micromoles per liter Standard Deviation 15.048
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Creatinine, Day 14	79.56 Micromoles per liter Standard Deviation 16.792	84.19 Micromoles per liter Standard Deviation 13.996	79.16 Micromoles per liter Standard Deviation 15.043	81.47 Micromoles per liter Standard Deviation 14.487
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Baseline (Day -2)	297.5 Micromoles per liter Standard Deviation 60.11	294.6 Micromoles per liter Standard Deviation 57.22	293.6 Micromoles per liter Standard Deviation 62.59	295.3 Micromoles per liter Standard Deviation 59.89
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Day 8	288.3 Micromoles per liter Standard Deviation 53.21	302.1 Micromoles per liter Standard Deviation 51.50	286.7 Micromoles per liter Standard Deviation 58.76	277.6 Micromoles per liter Standard Deviation 58.06
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Day 9	290.2 Micromoles per liter Standard Deviation 64.04	295.3 Micromoles per liter Standard Deviation 55.91	307.2 Micromoles per liter Standard Deviation 46.23	261.1 Micromoles per liter Standard Deviation 50.55
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Urate, Day 14	291.4 Micromoles per liter Standard Deviation 49.07	293.1 Micromoles per liter Standard Deviation 54.91	290.1 Micromoles per liter Standard Deviation 56.69	285.4 Micromoles per liter Standard Deviation 56.39
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Baseline (Day -2)	12.18 Micromoles per liter Standard Deviation 6.249	11.79 Micromoles per liter Standard Deviation 5.406	11.13 Micromoles per liter Standard Deviation 4.812	11.79 Micromoles per liter Standard Deviation 4.654
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Day 8	9.91 Micromoles per liter Standard Deviation 3.647	10.36 Micromoles per liter Standard Deviation 4.712	10.68 Micromoles per liter Standard Deviation 4.792	11.63 Micromoles per liter Standard Deviation 4.090
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Day 9	12.50 Micromoles per liter Standard Deviation 6.712	13.71 Micromoles per liter Standard Deviation 2.889	13.16 Micromoles per liter Standard Deviation 6.586	12.00 Micromoles per liter Standard Deviation 4.901
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Total Bilirubin, Day 14	11.42 Micromoles per liter Standard Deviation 4.666	12.89 Micromoles per liter Standard Deviation 7.360	12.40 Micromoles per liter Standard Deviation 5.214	11.53 Micromoles per liter Standard Deviation 4.675
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Baseline (Day -2)	2.22 Micromoles per liter Standard Deviation 0.988	2.12 Micromoles per liter Standard Deviation 0.916	2.05 Micromoles per liter Standard Deviation 0.834	2.07 Micromoles per liter Standard Deviation 0.686
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Day 8	1.86 Micromoles per liter Standard Deviation 0.689	1.90 Micromoles per liter Standard Deviation 0.796	1.97 Micromoles per liter Standard Deviation 0.811	2.22 Micromoles per liter Standard Deviation 0.934
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Day 9	2.23 Micromoles per liter Standard Deviation 1.033	2.39 Micromoles per liter Standard Deviation 0.646	2.30 Micromoles per liter Standard Deviation 1.127	2.23 Micromoles per liter Standard Deviation 0.772
Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin Direct Bilirubin, Day 14	2.06 Micromoles per liter Standard Deviation 0.781	2.21 Micromoles per liter Standard Deviation 1.113	2.22 Micromoles per liter Standard Deviation 0.887	2.10 Micromoles per liter Standard Deviation 0.844

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide, Day 8	-1.0 Millimoles per liter Standard Deviation 1.95	-0.6 Millimoles per liter Standard Deviation 1.62	-1.2 Millimoles per liter Standard Deviation 1.63	-1.2 Millimoles per liter Standard Deviation 2.12
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide, Day 9	-0.5 Millimoles per liter Standard Deviation 1.90	-1.1 Millimoles per liter Standard Deviation 1.45	-0.8 Millimoles per liter Standard Deviation 1.86	-0.1 Millimoles per liter Standard Deviation 1.10
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride, Day 8	0.7 Millimoles per liter Standard Deviation 1.92	-0.6 Millimoles per liter Standard Deviation 1.62	-0.2 Millimoles per liter Standard Deviation 1.83	-0.4 Millimoles per liter Standard Deviation 2.03
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride, Day 9	-0.6 Millimoles per liter Standard Deviation 1.71	-0.2 Millimoles per liter Standard Deviation 1.40	-1.0 Millimoles per liter Standard Deviation 1.58	-1.1 Millimoles per liter Standard Deviation 2.28
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride, Day 14	1.0 Millimoles per liter Standard Deviation 1.81	0.2 Millimoles per liter Standard Deviation 1.85	0.5 Millimoles per liter Standard Deviation 1.79	0.7 Millimoles per liter Standard Deviation 2.22
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate, Day 8	-0.009 Millimoles per liter Standard Deviation 0.1060	0.031 Millimoles per liter Standard Deviation 0.0971	0.018 Millimoles per liter Standard Deviation 0.0966	0.004 Millimoles per liter Standard Deviation 0.1388
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate, Day 9	0.016 Millimoles per liter Standard Deviation 0.0819	-0.001 Millimoles per liter Standard Deviation 0.0641	-0.016 Millimoles per liter Standard Deviation 0.0985	-0.005 Millimoles per liter Standard Deviation 0.0593
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate, Day 14	0.027 Millimoles per liter Standard Deviation 0.1225	0.000 Millimoles per liter Standard Deviation 0.0961	0.054 Millimoles per liter Standard Deviation 0.1156	0.047 Millimoles per liter Standard Deviation 0.1375
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium, Day 8	-0.02 Millimoles per liter Standard Deviation 0.458	-0.08 Millimoles per liter Standard Deviation 0.302	-0.12 Millimoles per liter Standard Deviation 0.401	-0.24 Millimoles per liter Standard Deviation 0.455
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium, Day 9	-0.05 Millimoles per liter Standard Deviation 0.299	-0.18 Millimoles per liter Standard Deviation 0.343	-0.03 Millimoles per liter Standard Deviation 0.346	-0.16 Millimoles per liter Standard Deviation 0.295
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium, Day 14	0.07 Millimoles per liter Standard Deviation 0.448	0.07 Millimoles per liter Standard Deviation 0.373	0.12 Millimoles per liter Standard Deviation 0.343	0.14 Millimoles per liter Standard Deviation 0.393
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium, Day 8	-0.4 Millimoles per liter Standard Deviation 2.23	-0.9 Millimoles per liter Standard Deviation 1.96	-0.9 Millimoles per liter Standard Deviation 2.25	-1.7 Millimoles per liter Standard Deviation 1.68
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium, Day 9	-0.4 Millimoles per liter Standard Deviation 0.97	-0.4 Millimoles per liter Standard Deviation 1.12	-0.4 Millimoles per liter Standard Deviation 2.07	-0.4 Millimoles per liter Standard Deviation 2.01
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium, Day 14	0.5 Millimoles per liter Standard Deviation 2.24	-0.1 Millimoles per liter Standard Deviation 1.87	0.8 Millimoles per liter Standard Deviation 2.13	0.1 Millimoles per liter Standard Deviation 2.12
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose, Day 8	-0.041 Millimoles per liter Standard Deviation 0.2820	0.029 Millimoles per liter Standard Deviation 0.3396	-0.023 Millimoles per liter Standard Deviation 0.3001	-0.024 Millimoles per liter Standard Deviation 0.2263
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose, Day 9	0.023 Millimoles per liter Standard Deviation 0.3045	-0.119 Millimoles per liter Standard Deviation 0.3171	0.040 Millimoles per liter Standard Deviation 0.1949	-0.139 Millimoles per liter Standard Deviation 0.2262
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose, Day 14	-0.033 Millimoles per liter Standard Deviation 0.3197	0.057 Millimoles per liter Standard Deviation 0.2787	-0.109 Millimoles per liter Standard Deviation 0.3220	0.046 Millimoles per liter Standard Deviation 0.2481
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol, Day 8	-0.148 Millimoles per liter Standard Deviation 0.4156	-0.116 Millimoles per liter Standard Deviation 0.4323	-0.054 Millimoles per liter Standard Deviation 0.3518	-0.201 Millimoles per liter Standard Deviation 0.3767
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol, Day 9	-0.036 Millimoles per liter Standard Deviation 0.3198	0.005 Millimoles per liter Standard Deviation 0.4131	0.081 Millimoles per liter Standard Deviation 0.4041	-0.186 Millimoles per liter Standard Deviation 0.3427
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol, Day 14	-0.102 Millimoles per liter Standard Deviation 0.5090	-0.181 Millimoles per liter Standard Deviation 0.4539	0.032 Millimoles per liter Standard Deviation 0.4605	-0.273 Millimoles per liter Standard Deviation 0.4303
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Magnesium, Day 8	-0.017 Millimoles per liter Standard Deviation 0.0443	-0.018 Millimoles per liter Standard Deviation 0.0379	-0.011 Millimoles per liter Standard Deviation 0.0364	0.005 Millimoles per liter Standard Deviation 0.0394
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Magnesium, Day 9	-0.020 Millimoles per liter Standard Deviation 0.0389	-0.001 Millimoles per liter Standard Deviation 0.0370	-0.013 Millimoles per liter Standard Deviation 0.0200	0.009 Millimoles per liter Standard Deviation 0.0328
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Magnesium, Day 14	-0.013 Millimoles per liter Standard Deviation 0.0431	0.002 Millimoles per liter Standard Deviation 0.0334	0.008 Millimoles per liter Standard Deviation 0.0379	0.003 Millimoles per liter Standard Deviation 0.0353
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides, Day 8	-0.019 Millimoles per liter Standard Deviation 0.3330	-0.111 Millimoles per liter Standard Deviation 0.3637	-0.002 Millimoles per liter Standard Deviation 0.2699	-0.100 Millimoles per liter Standard Deviation 0.3027
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides, Day 9	-0.050 Millimoles per liter Standard Deviation 0.3006	-0.097 Millimoles per liter Standard Deviation 0.2744	-0.153 Millimoles per liter Standard Deviation 0.1572	-0.151 Millimoles per liter Standard Deviation 0.1979
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides, Day 14	-0.052 Millimoles per liter Standard Deviation 0.2523	-0.127 Millimoles per liter Standard Deviation 0.3297	0.031 Millimoles per liter Standard Deviation 0.3383	0.035 Millimoles per liter Standard Deviation 0.2705
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap, Day 8	-0.2 Millimoles per liter Standard Deviation 2.02	0.1 Millimoles per liter Standard Deviation 1.35	0.0 Millimoles per liter Standard Deviation 1.92	-0.4 Millimoles per liter Standard Deviation 2.10
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap, Day 9	0.8 Millimoles per liter Standard Deviation 1.55	1.0 Millimoles per liter Standard Deviation 1.10	1.2 Millimoles per liter Standard Deviation 0.83	0.4 Millimoles per liter Standard Deviation 1.65
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap, Day 14	-0.4 Millimoles per liter Standard Deviation 1.63	-0.3 Millimoles per liter Standard Deviation 1.51	0.1 Millimoles per liter Standard Deviation 1.77	-0.8 Millimoles per liter Standard Deviation 1.75
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium, Day 8	-0.059 Millimoles per liter Standard Deviation 0.0737	-0.037 Millimoles per liter Standard Deviation 0.0795	-0.034 Millimoles per liter Standard Deviation 0.0744	-0.063 Millimoles per liter Standard Deviation 0.0617
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium, Day 9	0.001 Millimoles per liter Standard Deviation 0.0798	-0.025 Millimoles per liter Standard Deviation 0.1053	0.050 Millimoles per liter Standard Deviation 0.0825	-0.032 Millimoles per liter Standard Deviation 0.0780
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium, Day 14	-0.010 Millimoles per liter Standard Deviation 0.0754	-0.003 Millimoles per liter Standard Deviation 0.0555	0.042 Millimoles per liter Standard Deviation 0.0671	-0.020 Millimoles per liter Standard Deviation 0.0584
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide, Day 14	-0.2 Millimoles per liter Standard Deviation 1.46	0.2 Millimoles per liter Standard Deviation 1.92	0.1 Millimoles per liter Standard Deviation 2.05	0.3 Millimoles per liter Standard Deviation 1.79
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood Urea Nitrogen, Day 8	0.751 Millimoles per liter Standard Deviation 1.0248	0.890 Millimoles per liter Standard Deviation 0.7840	0.385 Millimoles per liter Standard Deviation 0.9919	0.225 Millimoles per liter Standard Deviation 1.1465
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood Urea Nitrogen, Day 9	0.557 Millimoles per liter Standard Deviation 0.2739	0.631 Millimoles per liter Standard Deviation 0.5449	0.154 Millimoles per liter Standard Deviation 0.7635	-0.060 Millimoles per liter Standard Deviation 0.7601
Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood Urea Nitrogen, Day 14	0.098 Millimoles per liter Standard Deviation 0.8195	0.173 Millimoles per liter Standard Deviation 0.9149	0.008 Millimoles per liter Standard Deviation 1.0030	0.010 Millimoles per liter Standard Deviation 1.1314

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 9	39.7 International units per liter Standard Deviation 69.36	-5.7 International units per liter Standard Deviation 18.29	63.9 International units per liter Standard Deviation 126.80	15.8 International units per liter Standard Deviation 29.26
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 14	-5.4 International units per liter Standard Deviation 15.88	-10.8 International units per liter Standard Deviation 20.17	-3.3 International units per liter Standard Deviation 16.67	-8.1 International units per liter Standard Deviation 15.00
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 9	1.9 International units per liter Standard Deviation 13.49	-11.6 International units per liter Standard Deviation 12.66	0.0 International units per liter Standard Deviation 6.78	4.0 International units per liter Standard Deviation 9.72
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 8	-2.1 International units per liter Standard Deviation 4.76	-0.9 International units per liter Standard Deviation 6.65	-2.5 International units per liter Standard Deviation 4.90	2.0 International units per liter Standard Deviation 8.06
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 9	0.7 International units per liter Standard Deviation 6.09	-0.9 International units per liter Standard Deviation 2.34	-0.6 International units per liter Standard Deviation 2.24	3.8 International units per liter Standard Deviation 9.87
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALT, Day 14	-2.3 International units per liter Standard Deviation 5.67	0.6 International units per liter Standard Deviation 8.68	-1.6 International units per liter Standard Deviation 6.24	1.7 International units per liter Standard Deviation 4.19
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 8	-2.2 International units per liter Standard Deviation 7.77	-0.7 International units per liter Standard Deviation 4.55	-1.2 International units per liter Standard Deviation 4.94	-1.7 International units per liter Standard Deviation 4.71
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 9	-3.6 International units per liter Standard Deviation 7.29	-0.1 International units per liter Standard Deviation 5.82	2.1 International units per liter Standard Deviation 5.84	1.1 International units per liter Standard Deviation 3.63
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase ALP, Day 14	-1.8 International units per liter Standard Deviation 6.18	-1.1 International units per liter Standard Deviation 7.33	0.5 International units per liter Standard Deviation 6.83	-2.0 International units per liter Standard Deviation 6.55
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 8	-1.6 International units per liter Standard Deviation 3.66	0.0 International units per liter Standard Deviation 11.09	-1.9 International units per liter Standard Deviation 2.49	-0.2 International units per liter Standard Deviation 3.73
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 9	0.9 International units per liter Standard Deviation 2.38	-0.3 International units per liter Standard Deviation 1.62	0.7 International units per liter Standard Deviation 2.40	1.1 International units per liter Standard Deviation 3.98
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase AST, Day 14	-1.5 International units per liter Standard Deviation 3.42	-0.7 International units per liter Standard Deviation 4.26	-1.2 International units per liter Standard Deviation 3.36	0.0 International units per liter Standard Deviation 3.11
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 8	-0.5 International units per liter Standard Deviation 2.42	-1.0 International units per liter Standard Deviation 2.44	-0.7 International units per liter Standard Deviation 1.85	-0.1 International units per liter Standard Deviation 3.51
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 9	-0.1 International units per liter Standard Deviation 1.97	-0.4 International units per liter Standard Deviation 1.03	0.3 International units per liter Standard Deviation 1.22	0.3 International units per liter Standard Deviation 0.67
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase GGT, Day 14	-1.0 International units per liter Standard Deviation 3.23	-1.3 International units per liter Standard Deviation 2.74	-0.8 International units per liter Standard Deviation 2.33	-1.3 International units per liter Standard Deviation 4.28
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 8	-18.9 International units per liter Standard Deviation 24.04	28.2 International units per liter Standard Deviation 446.48	-31.7 International units per liter Standard Deviation 89.14	-45.0 International units per liter Standard Deviation 97.35
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Creatine kinase, Day 14	8.8 International units per liter Standard Deviation 90.46	-30.8 International units per liter Standard Deviation 80.07	-22.5 International units per liter Standard Deviation 88.70	-22.0 International units per liter Standard Deviation 100.57
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase Lactate dehydrogenase, Day 8	-11.2 International units per liter Standard Deviation 15.99	-12.5 International units per liter Standard Deviation 20.51	-11.9 International units per liter Standard Deviation 14.29	-13.4 International units per liter Standard Deviation 17.89

Measure	Part 1: GSK3640254 500 mg n=42 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 1 : GSK3640254 500 mg n=40 Participants Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Part 2: Placebo n=40 Participants Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	Part 2: GSK3640254 500 mg n=40 Participants Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Baseline (Pre-dose, Day 1)	106.0 Millimeters of mercury Standard Deviation 9.39	106.7 Millimeters of mercury Standard Deviation 11.69	106.8 Millimeters of mercury Standard Deviation 9.03	105.4 Millimeters of mercury Standard Deviation 9.79
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 2	103.9 Millimeters of mercury Standard Deviation 8.18	104.5 Millimeters of mercury Standard Deviation 9.05	105.6 Millimeters of mercury Standard Deviation 9.78	105.7 Millimeters of mercury Standard Deviation 10.10
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 3	104.3 Millimeters of mercury Standard Deviation 9.82	103.8 Millimeters of mercury Standard Deviation 8.53	105.1 Millimeters of mercury Standard Deviation 9.41	105.3 Millimeters of mercury Standard Deviation 11.30
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 4	103.1 Millimeters of mercury Standard Deviation 9.37	103.5 Millimeters of mercury Standard Deviation 11.25	105.3 Millimeters of mercury Standard Deviation 8.73	105.7 Millimeters of mercury Standard Deviation 10.05
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 5	105.7 Millimeters of mercury Standard Deviation 9.50	103.3 Millimeters of mercury Standard Deviation 10.24	103.7 Millimeters of mercury Standard Deviation 8.65	106.8 Millimeters of mercury Standard Deviation 8.82
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 6	105.2 Millimeters of mercury Standard Deviation 8.80	104.7 Millimeters of mercury Standard Deviation 8.60	105.7 Millimeters of mercury Standard Deviation 8.42	108.4 Millimeters of mercury Standard Deviation 9.44
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 7	107.6 Millimeters of mercury Standard Deviation 10.34	106.7 Millimeters of mercury Standard Deviation 9.23	107.4 Millimeters of mercury Standard Deviation 8.68	107.4 Millimeters of mercury Standard Deviation 7.90
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 8	109.9 Millimeters of mercury Standard Deviation 9.03	108.1 Millimeters of mercury Standard Deviation 9.40	109.4 Millimeters of mercury Standard Deviation 8.95	109.1 Millimeters of mercury Standard Deviation 9.24
Part 2: Absolute Values for Vital Parameters: SBP and DBP ,SBP, Day 9	115.9 Millimeters of mercury Standard Deviation 9.72	104.2 Millimeters of mercury Standard Deviation 11.58	109.0 Millimeters of mercury Standard Deviation 7.48	105.8 Millimeters of mercury Standard Deviation 8.61
Part 2: Absolute Values for Vital Parameters: SBP and DBP SBP, Day 14	105.6 Millimeters of mercury Standard Deviation 9.51	108.0 Millimeters of mercury Standard Deviation 10.02	107.8 Millimeters of mercury Standard Deviation 9.38	106.3 Millimeters of mercury Standard Deviation 10.43
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Baseline (Pre-dose, Day 1)	61.1 Millimeters of mercury Standard Deviation 7.04	60.9 Millimeters of mercury Standard Deviation 6.61	62.1 Millimeters of mercury Standard Deviation 7.12	61.4 Millimeters of mercury Standard Deviation 6.18
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 2	59.6 Millimeters of mercury Standard Deviation 6.27	59.3 Millimeters of mercury Standard Deviation 6.32	60.9 Millimeters of mercury Standard Deviation 6.65	60.9 Millimeters of mercury Standard Deviation 6.10
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 3	60.9 Millimeters of mercury Standard Deviation 7.26	60.0 Millimeters of mercury Standard Deviation 7.46	61.0 Millimeters of mercury Standard Deviation 7.23	63.0 Millimeters of mercury Standard Deviation 7.80
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 4	59.8 Millimeters of mercury Standard Deviation 7.61	60.0 Millimeters of mercury Standard Deviation 7.36	61.0 Millimeters of mercury Standard Deviation 5.40	62.8 Millimeters of mercury Standard Deviation 6.10
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 5	60.3 Millimeters of mercury Standard Deviation 8.15	59.3 Millimeters of mercury Standard Deviation 6.23	59.1 Millimeters of mercury Standard Deviation 5.88	61.7 Millimeters of mercury Standard Deviation 5.44
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 6	60.3 Millimeters of mercury Standard Deviation 5.69	60.1 Millimeters of mercury Standard Deviation 6.46	61.6 Millimeters of mercury Standard Deviation 6.99	62.4 Millimeters of mercury Standard Deviation 7.00
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 7	61.0 Millimeters of mercury Standard Deviation 6.14	59.6 Millimeters of mercury Standard Deviation 6.89	61.1 Millimeters of mercury Standard Deviation 6.71	62.3 Millimeters of mercury Standard Deviation 6.28
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 8	62.3 Millimeters of mercury Standard Deviation 6.72	62.6 Millimeters of mercury Standard Deviation 7.23	61.4 Millimeters of mercury Standard Deviation 7.18	62.7 Millimeters of mercury Standard Deviation 7.03
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 9	66.2 Millimeters of mercury Standard Deviation 5.67	56.6 Millimeters of mercury Standard Deviation 3.83	61.3 Millimeters of mercury Standard Deviation 5.41	65.8 Millimeters of mercury Standard Deviation 5.37
Part 2: Absolute Values for Vital Parameters: SBP and DBP DBP, Day 14	61.6 Millimeters of mercury Standard Deviation 7.86	62.8 Millimeters of mercury Standard Deviation 6.65	61.8 Millimeters of mercury Standard Deviation 6.47	61.2 Millimeters of mercury Standard Deviation 6.91